NO332217B1 - Substituerte 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater, fremgangsmate for fremstilling derav, anvendelse derav samt legemiddel inneholdende minst ett slikt derivat. - Google Patents
Substituerte 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater, fremgangsmate for fremstilling derav, anvendelse derav samt legemiddel inneholdende minst ett slikt derivat. Download PDFInfo
- Publication number
- NO332217B1 NO332217B1 NO20035730A NO20035730A NO332217B1 NO 332217 B1 NO332217 B1 NO 332217B1 NO 20035730 A NO20035730 A NO 20035730A NO 20035730 A NO20035730 A NO 20035730A NO 332217 B1 NO332217 B1 NO 332217B1
- Authority
- NO
- Norway
- Prior art keywords
- diaza
- dec
- oxa
- spiro
- ene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- ZTUPVEXGISXGGN-UHFFFAOYSA-N 1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical class C1C=NOC11CCNCC1 ZTUPVEXGISXGGN-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- -1 (C 1-6 -alkyl)-aryl Chemical group 0.000 claims description 249
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 48
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 239000000460 chlorine Substances 0.000 claims description 42
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 41
- 229910052801 chlorine Inorganic materials 0.000 claims description 40
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 23
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 150000007513 acids Chemical class 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 150000003840 hydrochlorides Chemical class 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- LJXPWUAAAAXJBX-UHFFFAOYSA-N 2-methylallyl radical Chemical compound [CH2]C(C)=C LJXPWUAAAAXJBX-UHFFFAOYSA-N 0.000 claims description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 6
- 125000001637 1-naphthyl group Chemical class [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000001622 2-naphthyl group Chemical class [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 230000037005 anaesthesia Effects 0.000 claims description 6
- 238000001949 anaesthesia Methods 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- JIMSXLUBRRQALI-UHFFFAOYSA-N 2-phenylmethoxycyclopentan-1-amine Chemical compound NC1CCCC1OCC1=CC=CC=C1 JIMSXLUBRRQALI-UHFFFAOYSA-N 0.000 claims description 5
- YEDFKHQGIIPYQX-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)C=1SC(Cl)=CC=1)CC2 YEDFKHQGIIPYQX-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 125000006847 BOC protecting group Chemical group 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 4
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 239000004305 biphenyl Chemical group 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 3
- LFIDLDUNPSPAQT-UHFFFAOYSA-N 8-(4-methoxyphenyl)sulfonyl-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(CCC2)OCC=2C=CC=CC=2)CC1 LFIDLDUNPSPAQT-UHFFFAOYSA-N 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- ZHVDHKWFWHEYHT-UHFFFAOYSA-N (4-cycloheptylpiperazin-1-yl)-(8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)methanone Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2SC=CC=2)CC=1C(=O)N(CC1)CCN1C1CCCCCC1 ZHVDHKWFWHEYHT-UHFFFAOYSA-N 0.000 claims description 2
- RPBMCVGOBYQCFF-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-[4-(2-methylphenyl)piperazin-1-yl]methanone Chemical compound CC1=CC=CC=C1N1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)CC=2C=CC=CC=2)CC1 RPBMCVGOBYQCFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- XSFLBXNZRBRWKQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-1-[4-[8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]piperazin-1-yl]ethanone Chemical compound C1=C(F)C(F)=CC=C1CC(=O)N1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 XSFLBXNZRBRWKQ-UHFFFAOYSA-N 0.000 claims description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- ZIABGSHEOXSNMP-UHFFFAOYSA-N 3-(4-cycloheptylpiperazine-1-carbonyl)-n,n-dimethyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-sulfonamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)N2CCN(CC2)C2CCCCCC2)C1 ZIABGSHEOXSNMP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- WOVKNEMCUCDEHA-UHFFFAOYSA-N 8-(2,4-difluorobenzoyl)-n-(oxolan-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC2OCCC2)CC1 WOVKNEMCUCDEHA-UHFFFAOYSA-N 0.000 claims description 2
- UKYGQNRZCGJRNE-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-n-methyl-n-(pyridin-3-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)CC=1C(=O)N(C)CC1=CC=CN=C1 UKYGQNRZCGJRNE-UHFFFAOYSA-N 0.000 claims description 2
- GGCCIMUJTCTMLD-UHFFFAOYSA-N 8-(3-chloro-2-fluorobenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC1=C(Cl)C=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 GGCCIMUJTCTMLD-UHFFFAOYSA-N 0.000 claims description 2
- PYCWLEMUDBHXKI-UHFFFAOYSA-N 8-(3-chlorobenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCC=3SC=CC=3)CC2)=C1 PYCWLEMUDBHXKI-UHFFFAOYSA-N 0.000 claims description 2
- FLOYETIJZZFRGN-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)C=1C=CC(F)=CC=1)CC2 FLOYETIJZZFRGN-UHFFFAOYSA-N 0.000 claims description 2
- QCFWUDCIAWPNAH-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(CCC2)OCC=2C=CC=CC=2)CC1 QCFWUDCIAWPNAH-UHFFFAOYSA-N 0.000 claims description 2
- JOOLSNZOUDHHJP-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-[1-(naphthalen-2-ylamino)-1-oxopropan-2-yl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(F)C=C1 JOOLSNZOUDHHJP-UHFFFAOYSA-N 0.000 claims description 2
- AKOGMDVNLILWSW-UHFFFAOYSA-N 8-(4-methoxyphenyl)sulfonyl-n-(2-phenylcyclopropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(C2)C=2C=CC=CC=2)CC1 AKOGMDVNLILWSW-UHFFFAOYSA-N 0.000 claims description 2
- DEZZEZUBXGWZHP-UHFFFAOYSA-N 8-(5-bromo-2-methoxyphenyl)sulfonyl-n-cyclopentyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound COC1=CC=C(Br)C=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2CCCC2)CC1 DEZZEZUBXGWZHP-UHFFFAOYSA-N 0.000 claims description 2
- CFOMGGQBOSBOAS-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-(naphthalen-1-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C3=CC=CC=C3C=CC=2)CC1 CFOMGGQBOSBOAS-UHFFFAOYSA-N 0.000 claims description 2
- OHEWARDUTDUYMZ-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CN1CCCC1CCNC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1SC(Cl)=CC=1)CC2 OHEWARDUTDUYMZ-UHFFFAOYSA-N 0.000 claims description 2
- RAOVVGSTCFXOTK-UHFFFAOYSA-N 8-[2-(3-chlorophenoxy)acetyl]-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(OCC(=O)N2CCC3(ON=C(C3)C(=O)NCC=3SC=CC=3)CC2)=C1 RAOVVGSTCFXOTK-UHFFFAOYSA-N 0.000 claims description 2
- USCQZDXZCVGTAP-UHFFFAOYSA-N 8-[2-[(4-methylphenyl)sulfonylamino]-3-phenylpropanoyl]-n-(pyridin-3-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=NC=CC=2)CC1)CC1=CC=CC=C1 USCQZDXZCVGTAP-UHFFFAOYSA-N 0.000 claims description 2
- HLUWHWJJMBRFCU-UHFFFAOYSA-N 8-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCC1(ON=1)CC=1C(=O)NCC1=CC=CS1 HLUWHWJJMBRFCU-UHFFFAOYSA-N 0.000 claims description 2
- HLHTYXMHQWXWQP-UHFFFAOYSA-N 8-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]-n-(2-ethylsulfanylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCSCC)=NOC21CCN(C(=O)C=1C(=NOC=1C)C=1C(=CC=CC=1F)Cl)CC2 HLHTYXMHQWXWQP-UHFFFAOYSA-N 0.000 claims description 2
- BGHUZBPSUHSOKD-UHFFFAOYSA-N 8-acetyl-n-benzyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(C(=O)C)CCC11ON=C(C(=O)NCC=2C=CC=CC=2)C1 BGHUZBPSUHSOKD-UHFFFAOYSA-N 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000009132 Catalepsy Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000033830 Hot Flashes Diseases 0.000 claims description 2
- 206010060800 Hot flush Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 2
- 206010041415 Spastic paralysis Diseases 0.000 claims description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 206010047853 Waxy flexibility Diseases 0.000 claims description 2
- VYLJLJLAQDHSLL-UHFFFAOYSA-N [1-[3-(benzylcarbamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-2-methyl-1-oxopropan-2-yl] acetate Chemical compound C1CN(C(=O)C(C)(C)OC(=O)C)CCC11ON=C(C(=O)NCC=2C=CC=CC=2)C1 VYLJLJLAQDHSLL-UHFFFAOYSA-N 0.000 claims description 2
- LHXHKZQFOVPAPL-UHFFFAOYSA-N [3-methyl-4-(3-methylphenyl)piperazin-1-yl]-(8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)methanone Chemical compound CC1CN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC=CC=2)CCN1C1=CC=CC(C)=C1 LHXHKZQFOVPAPL-UHFFFAOYSA-N 0.000 claims description 2
- VPRQMJQMQKJOKJ-UHFFFAOYSA-N [8-(2,5-dichlorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-(4-thieno[2,3-d]pyrimidin-4-ylpiperazin-1-yl)methanone Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)N3CCN(CC3)C=3C=4C=CSC=4N=CN=3)CC2)=C1 VPRQMJQMQKJOKJ-UHFFFAOYSA-N 0.000 claims description 2
- IZGKYAURGORETM-UHFFFAOYSA-N [8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-[4-(1-phenylethyl)piperazin-1-yl]methanone Chemical compound C=1C=CC=CC=1C(C)N(CC1)CCN1C(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(C)C=C1 IZGKYAURGORETM-UHFFFAOYSA-N 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- UKYJZUAGQPBCOY-UHFFFAOYSA-N benzyl 4-[8-(4-fluorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]piperazine-1-carboxylate Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CC2)C(=O)OCC=2C=CC=CC=2)CC1 UKYJZUAGQPBCOY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- UXOLDCOJRAMLTQ-ZZXKWVIFSA-N ethyl (2e)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N/O UXOLDCOJRAMLTQ-ZZXKWVIFSA-N 0.000 claims description 2
- BMWDNPYTKYCKIH-UHFFFAOYSA-N ethyl 3-[[8-(2-methyl-5-nitrophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]propanoate Chemical compound C1C(C(=O)NCCC(=O)OCC)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(C=1)[N+]([O-])=O)C)CC2 BMWDNPYTKYCKIH-UHFFFAOYSA-N 0.000 claims description 2
- QDJZXRZZBHVXBG-UHFFFAOYSA-N ethyl 3-[[8-[(7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methylsulfonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]propanoate Chemical compound C1C(C(=O)NCCC(=O)OCC)=NOC21CCN(S(=O)(=O)CC13C(CC(CC1)C3(C)C)=O)CC2 QDJZXRZZBHVXBG-UHFFFAOYSA-N 0.000 claims description 2
- VELQTNVKKXEIBD-UHFFFAOYSA-N ethyl 4-[[8-(2-methyl-5-nitrophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(C=1)[N+]([O-])=O)C)CC2 VELQTNVKKXEIBD-UHFFFAOYSA-N 0.000 claims description 2
- XGIABLWVEATFAC-UHFFFAOYSA-N ethyl 4-[[8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1C=C(C=CC=1)C(F)(F)F)CC2 XGIABLWVEATFAC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- VGUQZTQQQZXETC-UHFFFAOYSA-N methyl 3-(1h-indol-3-yl)-2-[[8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]propanoate Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)OC)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 VGUQZTQQQZXETC-UHFFFAOYSA-N 0.000 claims description 2
- IDZBQFFHUDFIAF-UHFFFAOYSA-N methyl 4-oxo-4-[3-(thiophen-2-ylmethylcarbamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]butanoate Chemical compound C1CN(C(=O)CCC(=O)OC)CCC11ON=C(C(=O)NCC=2SC=CC=2)C1 IDZBQFFHUDFIAF-UHFFFAOYSA-N 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- QCRPURZINMXPEJ-UHFFFAOYSA-N n'-[4-(diethylamino)benzoyl]-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbohydrazide Chemical compound C1=CC(N(CC)CC)=CC=C1C(=O)NNC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1SC=CC=1)CC2 QCRPURZINMXPEJ-UHFFFAOYSA-N 0.000 claims description 2
- SDFCUZFKFZRPJM-UHFFFAOYSA-N n,n-dimethyl-3-(4-thieno[2,3-d]pyrimidin-4-ylpiperazine-1-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-sulfonamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)N2CCN(CC2)C=2C=3C=CSC=3N=CN=2)C1 SDFCUZFKFZRPJM-UHFFFAOYSA-N 0.000 claims description 2
- LBKBAGGMDDLKBN-UHFFFAOYSA-N n,n-dimethyl-3-[4-(3-phenylpropyl)piperazine-1-carbonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-sulfonamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)N2CCN(CCCC=3C=CC=CC=3)CC2)C1 LBKBAGGMDDLKBN-UHFFFAOYSA-N 0.000 claims description 2
- OXAWUHBSVONBDE-UHFFFAOYSA-N n,n-dimethyl-3-[4-(naphthalen-2-ylmethyl)piperazine-1-carbonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-sulfonamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)N2CCN(CC=3C=C4C=CC=CC4=CC=3)CC2)C1 OXAWUHBSVONBDE-UHFFFAOYSA-N 0.000 claims description 2
- AYQKGHUGIVCQMN-UHFFFAOYSA-N n-(2-cyanoethyl)-8-[2-[(4-methylphenyl)sulfonylamino]-3-phenylpropanoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)N1CCC2(ON=C(C2)C(=O)NCCC#N)CC1)CC1=CC=CC=C1 AYQKGHUGIVCQMN-UHFFFAOYSA-N 0.000 claims description 2
- LOIHHDDJXKCVAQ-UHFFFAOYSA-N n-(2-methylpropyl)-8-(naphthalene-1-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCC(C)C)=NOC21CCN(C(=O)C=1C3=CC=CC=C3C=CC=1)CC2 LOIHHDDJXKCVAQ-UHFFFAOYSA-N 0.000 claims description 2
- RSGDZJCLIXQBLC-UHFFFAOYSA-N n-(2-methylpropyl)-8-propylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(S(=O)(=O)CCC)CCC11ON=C(C(=O)NCC(C)C)C1 RSGDZJCLIXQBLC-UHFFFAOYSA-N 0.000 claims description 2
- GYMWQSLSXGSPTM-UHFFFAOYSA-N n-(2-phenylmethoxycyclopentyl)-8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)NC3C(CCC3)OCC=3C=CC=CC=3)CC2)=C1 GYMWQSLSXGSPTM-UHFFFAOYSA-N 0.000 claims description 2
- JOIAQXWBOPGKMF-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)NCC3CC3)CC2)=C1 JOIAQXWBOPGKMF-UHFFFAOYSA-N 0.000 claims description 2
- NYKXXZRLTJFDNX-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=C(Cl)C=CC=3)CC2)=C1 NYKXXZRLTJFDNX-UHFFFAOYSA-N 0.000 claims description 2
- HNGATMNFAGEMOE-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC1=CC=CC(CNC(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC=CC=2)=C1 HNGATMNFAGEMOE-UHFFFAOYSA-N 0.000 claims description 2
- DJACKYNRVNNXJA-UHFFFAOYSA-N n-[1-(4-chlorophenyl)propan-2-yl]-8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2SC(Cl)=CC=2)CC=1C(=O)NC(C)CC1=CC=C(Cl)C=C1 DJACKYNRVNNXJA-UHFFFAOYSA-N 0.000 claims description 2
- AXVAUCGLQBYQNS-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-n-methyl-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(C)C(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 AXVAUCGLQBYQNS-UHFFFAOYSA-N 0.000 claims description 2
- IOJVIQUJBQRMMN-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1C=CC(OC(F)(F)F)=CC=1)CC2 IOJVIQUJBQRMMN-UHFFFAOYSA-N 0.000 claims description 2
- OWJSZJJDAOPPDE-UHFFFAOYSA-N n-benzhydryl-8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 OWJSZJJDAOPPDE-UHFFFAOYSA-N 0.000 claims description 2
- JCQBIRPNKWLAMG-UHFFFAOYSA-N n-benzyl-8-(2,5-dimethylfuran-3-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound O1C(C)=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=CC=CC=3)CC2)=C1C JCQBIRPNKWLAMG-UHFFFAOYSA-N 0.000 claims description 2
- BMLDLUBRNTWDTM-UHFFFAOYSA-N n-benzyl-8-(2-ethylsulfanylpyridine-3-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CCSC1=NC=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=CC=CC=2)CC1 BMLDLUBRNTWDTM-UHFFFAOYSA-N 0.000 claims description 2
- KKTAJIYATRIXLV-UHFFFAOYSA-N n-benzyl-8-(2-phenoxypyridine-3-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)C(=O)C=2C(=NC=CC=2)OC=2C=CC=CC=2)CC=1C(=O)NCC1=CC=CC=C1 KKTAJIYATRIXLV-UHFFFAOYSA-N 0.000 claims description 2
- LJFDGLLXOODMSN-UHFFFAOYSA-N n-benzyl-8-(3-chloro-4-fluorobenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=CC=CC=2)CC1 LJFDGLLXOODMSN-UHFFFAOYSA-N 0.000 claims description 2
- YZDBHYFUHUJKEB-UHFFFAOYSA-N n-benzyl-8-[2-(2-methoxyethoxy)acetyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC11ON=C(C(=O)NCC=2C=CC=CC=2)C1 YZDBHYFUHUJKEB-UHFFFAOYSA-N 0.000 claims description 2
- CZUPIKCEUWLSSV-UHFFFAOYSA-N n-benzyl-n-(2-cyanoethyl)-8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N(CCC#N)CC=2C=CC=CC=2)CC1 CZUPIKCEUWLSSV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- ZGFWIYJTRCPIGN-UHFFFAOYSA-N n-naphthalen-2-yl-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC=2C=C3C=CC=CC3=CC=2)CC1 ZGFWIYJTRCPIGN-UHFFFAOYSA-N 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000002276 neurotropic effect Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000001777 nootropic effect Effects 0.000 claims description 2
- 206010029864 nystagmus Diseases 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 150000003235 pyrrolidines Chemical class 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 238000007127 saponification reaction Methods 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- QUMCZYNURZHNKI-UHFFFAOYSA-N tert-butyl 4-methyl-2-[(8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl)amino]pentanoate Chemical compound C1C(C(=O)NC(CC(C)C)C(=O)OC(C)(C)C)=NOC21CCN(S(=O)(=O)C=1SC=CC=1)CC2 QUMCZYNURZHNKI-UHFFFAOYSA-N 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- RUWYXVWIZQHQBF-UHFFFAOYSA-N 8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(O)=O)CC1 RUWYXVWIZQHQBF-UHFFFAOYSA-N 0.000 claims 1
- ZMBZRBYEOQAMRJ-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-[1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2CN(CC=3C=C4C=CC=CC4=CC=3)CC2)CC1 ZMBZRBYEOQAMRJ-UHFFFAOYSA-N 0.000 claims 1
- CKZQCLNKVBNLSN-UHFFFAOYSA-N 8-benzylsulfonyl-n-[4-(diethoxyphosphorylmethyl)phenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)C(C1)=NOC21CCN(S(=O)(=O)CC=1C=CC=CC=1)CC2 CKZQCLNKVBNLSN-UHFFFAOYSA-N 0.000 claims 1
- QCJLGLQFMDKMCL-UHFFFAOYSA-N CN(C)S(=O)(=O)N1CCC2(CC(=NO2)C(O)=O)CC1.COc1cc(OC)cc(c1)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1ccc(Cl)s1 Chemical compound CN(C)S(=O)(=O)N1CCC2(CC(=NO2)C(O)=O)CC1.COc1cc(OC)cc(c1)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1ccc(Cl)s1 QCJLGLQFMDKMCL-UHFFFAOYSA-N 0.000 claims 1
- NHCYJHOCPSIXFS-UHFFFAOYSA-N CN(C)S(=O)(=O)N1CCC2(CC(=NO2)C(O)=O)CC1.Fc1ccc(cc1)C1=CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)Cc1ccccc1 Chemical compound CN(C)S(=O)(=O)N1CCC2(CC(=NO2)C(O)=O)CC1.Fc1ccc(cc1)C1=CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)Cc1ccccc1 NHCYJHOCPSIXFS-UHFFFAOYSA-N 0.000 claims 1
- WFVWTZZGBSYBQE-UHFFFAOYSA-N COC(C=CC(CN)=C1)=C1OC.O=C(C(C1)=NOC1(CC1)CCN1S(CC1=CC=CC=C1)(=O)=O)N1CCN(CCCC2=CC=CC=C2)CC1 Chemical compound COC(C=CC(CN)=C1)=C1OC.O=C(C(C1)=NOC1(CC1)CCN1S(CC1=CC=CC=C1)(=O)=O)N1CCN(CCCC2=CC=CC=C2)CC1 WFVWTZZGBSYBQE-UHFFFAOYSA-N 0.000 claims 1
- LPEKHTSPBFRZJJ-UHFFFAOYSA-N ClC1=NC=CC=C1C(=O)N1CCC2(CC(=NO2)C(=O)O)CC1.CC1=C(C=CC(=C1)C)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C)C=C2 Chemical compound ClC1=NC=CC=C1C(=O)N1CCC2(CC(=NO2)C(=O)O)CC1.CC1=C(C=CC(=C1)C)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)C2=CC=C(C)C=C2 LPEKHTSPBFRZJJ-UHFFFAOYSA-N 0.000 claims 1
- YOTIZHOFPCVONU-UHFFFAOYSA-N FC(F)(F)SC1=CC=C(C(=O)N2CCC3(CC(=NO3)C(=O)O)CC2)C=C1.C1(=CC=CC=C1)CS(=O)(=O)N1CCC2(CC(=NO2)C(=O)N2CCN(CC2)C2=NC=CC=C2)CC1 Chemical compound FC(F)(F)SC1=CC=C(C(=O)N2CCC3(CC(=NO3)C(=O)O)CC2)C=C1.C1(=CC=CC=C1)CS(=O)(=O)N1CCC2(CC(=NO2)C(=O)N2CCN(CC2)C2=NC=CC=C2)CC1 YOTIZHOFPCVONU-UHFFFAOYSA-N 0.000 claims 1
- GTWYZZOGWYOPLZ-UHFFFAOYSA-N OC(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1cc(Cl)ccc1Cl.O=C(N1CCN(CCCc2ccccc2)CC1)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1cccs1 Chemical compound OC(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1cc(Cl)ccc1Cl.O=C(N1CCN(CCCc2ccccc2)CC1)C1=NOC2(C1)CCN(CC2)S(=O)(=O)c1cccs1 GTWYZZOGWYOPLZ-UHFFFAOYSA-N 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- FIKMMZSBSHOBGL-UHFFFAOYSA-N S1C(=CC=C1)S(=O)(=O)N1CCC2(CC(=NO2)C(=O)O)CC1.ClC1=CC=C(C=C1)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)CC2=CC=CC=C2 Chemical compound S1C(=CC=C1)S(=O)(=O)N1CCC2(CC(=NO2)C(=O)O)CC1.ClC1=CC=C(C=C1)N1CCN(CC1)C(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)CC2=CC=CC=C2 FIKMMZSBSHOBGL-UHFFFAOYSA-N 0.000 claims 1
- JDCGWTQYWRDIKC-UHFFFAOYSA-N [4-(naphthalen-2-ylmethyl)piperazin-1-yl]-[8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]methanone Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)N3CCN(CC=4C=C5C=CC=CC5=CC=4)CC3)CC2)=C1 JDCGWTQYWRDIKC-UHFFFAOYSA-N 0.000 claims 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 claims 1
- HTCLRQGJGPUTPL-UHFFFAOYSA-N n-benzyl-8-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2F)Cl)C=1C(=O)N(CC1)CCC1(ON=1)CC=1C(=O)NCC1=CC=CC=C1 HTCLRQGJGPUTPL-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 230000027455 binding Effects 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000008351 acetate buffer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- YKNMBTZOEVIJCM-UHFFFAOYSA-N dec-2-ene Chemical class CCCCCCCC=CC YKNMBTZOEVIJCM-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- AKHYYOFKMVRZKH-UHFFFAOYSA-N n-benzyl-8-(2-phenylmethoxyacetyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CC2(ON=C(C2)C(=O)NCC=2C=CC=CC=2)CCN1C(=O)COCC1=CC=CC=C1 AKHYYOFKMVRZKH-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 102000018674 Sodium Channels Human genes 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- PSGWHRNZDXQSRB-UHFFFAOYSA-N 8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)C=1SC=CC=1)CC2 PSGWHRNZDXQSRB-UHFFFAOYSA-N 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- WOLDSOXASZRDQH-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(Cl)C=1)Cl)CC2 WOLDSOXASZRDQH-UHFFFAOYSA-N 0.000 description 2
- OYRVRDRKPMBHCN-UHFFFAOYSA-N 8-(4-methylphenyl)sulfonyl-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(CCC2)OCC=2C=CC=CC=2)CC1 OYRVRDRKPMBHCN-UHFFFAOYSA-N 0.000 description 2
- OZCFKDIKAXQBLR-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(CCC2)OCC=2C=CC=CC=2)CC1 OZCFKDIKAXQBLR-UHFFFAOYSA-N 0.000 description 2
- PEQZOGMNNBDAMT-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11ON=C(C(O)=O)C1 PEQZOGMNNBDAMT-UHFFFAOYSA-N 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000002381 Brain Hypoxia Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- JNBHWETXIFZBSB-UHFFFAOYSA-N n-benzyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCNCC2)CC=1C(=O)NCC1=CC=CC=C1 JNBHWETXIFZBSB-UHFFFAOYSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PRWAKWPESSXECM-UHFFFAOYSA-N tert-butyl 3-(benzylcarbamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11ON=C(C(=O)NCC=2C=CC=CC=2)C1 PRWAKWPESSXECM-UHFFFAOYSA-N 0.000 description 2
- PDTZMULNKGUIEJ-UHFFFAOYSA-N tert-butyl 4-methylidenepiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=C)CC1 PDTZMULNKGUIEJ-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HDPPLEXBCIKKLK-UHFFFAOYSA-N (4-cycloheptylpiperazin-1-yl)-[8-(4-fluorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]methanone Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CC2)C2CCCCCC2)CC1 HDPPLEXBCIKKLK-UHFFFAOYSA-N 0.000 description 1
- SDRUTIVQQWKDOU-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)CC=1C(=O)N(CC1)CCN1C1=CC=CC=N1 SDRUTIVQQWKDOU-UHFFFAOYSA-N 0.000 description 1
- WBBJDJPWMACHFW-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-[4-(3-phenylpropyl)piperazin-1-yl]methanone Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)CC=1C(=O)N(CC1)CCN1CCCC1=CC=CC=C1 WBBJDJPWMACHFW-UHFFFAOYSA-N 0.000 description 1
- BXLLMBABWWOTTJ-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-[4-(4-chlorophenyl)piperazin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1N1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)CC=2C=CC=CC=2)CC1 BXLLMBABWWOTTJ-UHFFFAOYSA-N 0.000 description 1
- FOHXZBGWQZQLFM-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-[4-(4-fluorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)CC=2C=CC=CC=2)CC1 FOHXZBGWQZQLFM-UHFFFAOYSA-N 0.000 description 1
- LMGHPYAMWFVQFF-UHFFFAOYSA-N (8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)-[4-(naphthalen-2-ylmethyl)piperazin-1-yl]methanone Chemical compound C1CN(CC=2C=C3C=CC=CC3=CC=2)CCN1C(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)CC1=CC=CC=C1 LMGHPYAMWFVQFF-UHFFFAOYSA-N 0.000 description 1
- MYTPKHMBCLTSCI-UHFFFAOYSA-N 1-[4-[8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]piperazin-1-yl]-2-phenylethanone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CC2)C(=O)CC=2C=CC=CC=2)CC1 MYTPKHMBCLTSCI-UHFFFAOYSA-N 0.000 description 1
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
- YKVRQNSFUGFHHJ-UHFFFAOYSA-N 2-phenylmethoxycyclopentan-1-amine;hydrochloride Chemical compound Cl.NC1CCCC1OCC1=CC=CC=C1 YKVRQNSFUGFHHJ-UHFFFAOYSA-N 0.000 description 1
- RTMDFFQGTUDFIW-UHFFFAOYSA-N 3-[4-[(4-tert-butylphenyl)methyl]piperazine-1-carbonyl]-n,n-dimethyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-sulfonamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)N2CCN(CC=3C=CC(=CC=3)C(C)(C)C)CC2)C1 RTMDFFQGTUDFIW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BOPOFXRNGIJLJN-UHFFFAOYSA-N 4-methylidenepiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=C)CC1 BOPOFXRNGIJLJN-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- SORSTNOXGOXWAO-UHFFFAOYSA-N 5-chlorothiophene-2-sulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)S1 SORSTNOXGOXWAO-UHFFFAOYSA-N 0.000 description 1
- VHLCAGGATJVXQO-UHFFFAOYSA-N 8-(2,3-dichlorobenzoyl)-n-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NC=3C=CC=CC=3)CC2)=C1Cl VHLCAGGATJVXQO-UHFFFAOYSA-N 0.000 description 1
- WZVASLAXHKBYNE-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-n-[1-(naphthalen-2-ylamino)-1-oxopropan-2-yl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC(Cl)=CC=C1Cl WZVASLAXHKBYNE-UHFFFAOYSA-N 0.000 description 1
- DVTMDEZAEOVMOL-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-n-[1-[(3-methoxyphenyl)methyl]pyrrolidin-3-yl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound COC1=CC=CC(CN2CC(CC2)NC(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=C1 DVTMDEZAEOVMOL-UHFFFAOYSA-N 0.000 description 1
- HNLGKAPXWAPRCL-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-n-[3-(2-methylpiperidin-1-yl)propyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CC1CCCCN1CCCNC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(Cl)C=1)Cl)CC2 HNLGKAPXWAPRCL-UHFFFAOYSA-N 0.000 description 1
- JVUAAUPOZHNXKC-UHFFFAOYSA-N 8-(2,5-dichlorophenyl)sulfonyl-n-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(CNC(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=C1 JVUAAUPOZHNXKC-UHFFFAOYSA-N 0.000 description 1
- DZPNLZDYKFFPME-UHFFFAOYSA-N 8-(2,6-difluoro-3-methylbenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CC1=CC=C(F)C(C(=O)N2CCC3(ON=C(C3)C(=O)NCC=3SC=CC=3)CC2)=C1F DZPNLZDYKFFPME-UHFFFAOYSA-N 0.000 description 1
- YRCNPFGZGODODU-UHFFFAOYSA-N 8-(2-chloro-4-nitrobenzoyl)-n-cyclopentyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NC2CCCC2)CC1 YRCNPFGZGODODU-UHFFFAOYSA-N 0.000 description 1
- LRSBIYWVKXRQKM-UHFFFAOYSA-N 8-(2-chlorobenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 LRSBIYWVKXRQKM-UHFFFAOYSA-N 0.000 description 1
- NCWIKFSDKFZKOS-UHFFFAOYSA-N 8-(2-chlorophenyl)sulfonyl-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 NCWIKFSDKFZKOS-UHFFFAOYSA-N 0.000 description 1
- QROJVJHKBLNTFG-UHFFFAOYSA-N 8-(2-chloropyridine-3-carbonyl)-n-cyclopentyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NC2CCCC2)CC1 QROJVJHKBLNTFG-UHFFFAOYSA-N 0.000 description 1
- WNVLAMLGMRQHGO-UHFFFAOYSA-N 8-(3-chloro-4-fluorobenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 WNVLAMLGMRQHGO-UHFFFAOYSA-N 0.000 description 1
- QUIOHKMOKJTVJM-UHFFFAOYSA-N 8-(3-chloro-4-fluorophenyl)sulfonyl-n-(2-pyrrolidin-1-ylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=C(Cl)C(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCCN2CCCC2)CC1 QUIOHKMOKJTVJM-UHFFFAOYSA-N 0.000 description 1
- PHOOFUUOBYYSSR-UHFFFAOYSA-N 8-(4-bromo-3-methylbenzoyl)-n-(2-methylpropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCC(C)C)=NOC21CCN(C(=O)C=1C=C(C)C(Br)=CC=1)CC2 PHOOFUUOBYYSSR-UHFFFAOYSA-N 0.000 description 1
- ITURRKAKDFAXFC-UHFFFAOYSA-N 8-(4-bromo-3-methylbenzoyl)-n-(pyridin-4-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=C(Br)C(C)=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=CN=CC=3)CC2)=C1 ITURRKAKDFAXFC-UHFFFAOYSA-N 0.000 description 1
- UMBQWJDTWRHIKH-UHFFFAOYSA-N 8-(4-bromobenzoyl)-n-(2-ethylsulfanylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCSCC)=NOC21CCN(C(=O)C=1C=CC(Br)=CC=1)CC2 UMBQWJDTWRHIKH-UHFFFAOYSA-N 0.000 description 1
- XWTXBMKWGHPUFK-UHFFFAOYSA-N 8-(4-bromobenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(Br)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 XWTXBMKWGHPUFK-UHFFFAOYSA-N 0.000 description 1
- PCIFTPWJICZPSG-UHFFFAOYSA-N 8-(4-bromobenzoyl)-n-[(5-methylfuran-2-yl)methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound O1C(C)=CC=C1CNC(=O)C(C1)=NOC21CCN(C(=O)C=1C=CC(Br)=CC=1)CC2 PCIFTPWJICZPSG-UHFFFAOYSA-N 0.000 description 1
- WLURBQDMYJXOCP-UHFFFAOYSA-N 8-(4-bromobenzoyl)-n-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(Br)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NC=2C=CC=CC=2)CC1 WLURBQDMYJXOCP-UHFFFAOYSA-N 0.000 description 1
- ZDJHJCZBERPTQM-UHFFFAOYSA-N 8-(4-chlorophenyl)sulfonyl-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 ZDJHJCZBERPTQM-UHFFFAOYSA-N 0.000 description 1
- ARYGUIOMRAQAEZ-UHFFFAOYSA-N 8-(4-ethylbenzoyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(CC)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 ARYGUIOMRAQAEZ-UHFFFAOYSA-N 0.000 description 1
- HPLAVFPHHPSFQU-UHFFFAOYSA-N 8-(4-fluorobenzoyl)-n-(2-methylpropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCC(C)C)=NOC21CCN(C(=O)C=1C=CC(F)=CC=1)CC2 HPLAVFPHHPSFQU-UHFFFAOYSA-N 0.000 description 1
- OMXKJIZAFUPDOH-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-(3-imidazol-1-ylpropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCCCN2C=NC=C2)CC1 OMXKJIZAFUPDOH-UHFFFAOYSA-N 0.000 description 1
- CVUPGBHIZMCVTJ-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-(3-phenylpropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCCCC=2C=CC=CC=2)CC1 CVUPGBHIZMCVTJ-UHFFFAOYSA-N 0.000 description 1
- BIMYGJICMWRSFD-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-[1-(4-nitrophenyl)ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(F)C=C1 BIMYGJICMWRSFD-UHFFFAOYSA-N 0.000 description 1
- ZBDPXCDTOPAVTJ-UHFFFAOYSA-N 8-(4-fluorophenyl)sulfonyl-n-[2-[3-(trifluoromethyl)phenyl]ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCCC=2C=C(C=CC=2)C(F)(F)F)CC1 ZBDPXCDTOPAVTJ-UHFFFAOYSA-N 0.000 description 1
- YBILHBLUFYUAAM-UHFFFAOYSA-N 8-(4-methoxybenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC2(ON=C(C2)C(O)=O)CC1 YBILHBLUFYUAAM-UHFFFAOYSA-N 0.000 description 1
- NDGOCFJWEBXIHQ-UHFFFAOYSA-N 8-(4-methylphenyl)sulfonyl-n-(2-phenylcyclopropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC2C(C2)C=2C=CC=CC=2)CC1 NDGOCFJWEBXIHQ-UHFFFAOYSA-N 0.000 description 1
- AAWSNBDOPGWKOW-UHFFFAOYSA-N 8-(4-methylphenyl)sulfonyl-n-(4-phenoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)CC1 AAWSNBDOPGWKOW-UHFFFAOYSA-N 0.000 description 1
- ZOHRBEYFZMULRO-UHFFFAOYSA-N 8-(4-nitrophenyl)sulfonyl-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 ZOHRBEYFZMULRO-UHFFFAOYSA-N 0.000 description 1
- JTFLBLLPKHGNKF-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-(2,2-diphenylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 JTFLBLLPKHGNKF-UHFFFAOYSA-N 0.000 description 1
- RQPTVOACPLFGAN-UHFFFAOYSA-N 8-(5-chlorothiophen-2-yl)sulfonyl-n-[3-(n-methylanilino)propyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=CC=CC=1N(C)CCCNC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(Cl)S1 RQPTVOACPLFGAN-UHFFFAOYSA-N 0.000 description 1
- FMHWZDXNCFEMEO-UHFFFAOYSA-N 8-(5-fluoro-2-methylphenyl)sulfonyl-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CC1=CC=C(F)C=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 FMHWZDXNCFEMEO-UHFFFAOYSA-N 0.000 description 1
- IQGFXCDYQYRDCH-UHFFFAOYSA-N 8-(5-tert-butyl-2-methylfuran-3-carbonyl)-n-(2-methylpropyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCC(C)C)=NOC21CCN(C(=O)C1=C(OC(=C1)C(C)(C)C)C)CC2 IQGFXCDYQYRDCH-UHFFFAOYSA-N 0.000 description 1
- BICQWZLGVGBCKJ-UHFFFAOYSA-N 8-(5-tert-butyl-2-methylfuran-3-carbonyl)-n-cyclopentyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NC3CCCC3)CC2)=C1C BICQWZLGVGBCKJ-UHFFFAOYSA-N 0.000 description 1
- ADAFMRSNUNVYKD-UHFFFAOYSA-N 8-(benzenesulfonyl)-n-[2-(dimethylamino)ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCN(C)C)=NOC21CCN(S(=O)(=O)C=1C=CC=CC=1)CC2 ADAFMRSNUNVYKD-UHFFFAOYSA-N 0.000 description 1
- QJNMRJMGKCUCGE-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(O)=O)C1 QJNMRJMGKCUCGE-UHFFFAOYSA-N 0.000 description 1
- VJHFIAVYMAJQDB-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-n-(2-ethylsulfanylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCSCC)=NOC21CCN(S(=O)(=O)N(C)C)CC2 VJHFIAVYMAJQDB-UHFFFAOYSA-N 0.000 description 1
- UPEPEEAISFWFAE-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-n-(2-phenylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)NCCC=2C=CC=CC=2)C1 UPEPEEAISFWFAE-UHFFFAOYSA-N 0.000 description 1
- BWNNRHDTCSQLJF-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)NC2C(CCC2)OCC=2C=CC=CC=2)C1 BWNNRHDTCSQLJF-UHFFFAOYSA-N 0.000 description 1
- UIPANGYLELCYKQ-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-n-[2-(n-ethyl-3-methylanilino)ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=CC(C)=CC=1N(CC)CCNC(=O)C(C1)=NOC21CCN(S(=O)(=O)N(C)C)CC2 UIPANGYLELCYKQ-UHFFFAOYSA-N 0.000 description 1
- PGZOLIAKNYMZDZ-UHFFFAOYSA-N 8-(dimethylsulfamoyl)-n-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)NCC=2C=C(F)C(=CC=2)C(F)(F)F)C1 PGZOLIAKNYMZDZ-UHFFFAOYSA-N 0.000 description 1
- BYUYADUKBRWTFT-UHFFFAOYSA-N 8-(naphthalene-1-carbonyl)-n-(thiophen-2-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)C(=O)C=2C3=CC=CC=C3C=CC=2)CC=1C(=O)NCC1=CC=CS1 BYUYADUKBRWTFT-UHFFFAOYSA-N 0.000 description 1
- LKTWYCXLXLKHDB-UHFFFAOYSA-N 8-[(7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methylsulfonyl]-n-(2-ethylsulfanylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCSCC)=NOC21CCN(S(=O)(=O)CC13C(CC(CC1)C3(C)C)=O)CC2 LKTWYCXLXLKHDB-UHFFFAOYSA-N 0.000 description 1
- COHFZGQIJDTESS-UHFFFAOYSA-N 8-[2-chloro-5-(trifluoromethyl)benzoyl]-n-(cyclopropylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N2CCC3(ON=C(C3)C(=O)NCC3CC3)CC2)=C1 COHFZGQIJDTESS-UHFFFAOYSA-N 0.000 description 1
- YVEGSGJTWJCSAG-UHFFFAOYSA-N 8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)C=1C=CC(OC(F)(F)F)=CC=1)CC2 YVEGSGJTWJCSAG-UHFFFAOYSA-N 0.000 description 1
- WNBJLBQIPMDJHY-UHFFFAOYSA-N 8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC21CCN(S(=O)(=O)CC=1C=CC=CC=1)CC2 WNBJLBQIPMDJHY-UHFFFAOYSA-N 0.000 description 1
- VNMYTZXTQQOUCR-UHFFFAOYSA-N 8-benzylsulfonyl-n-(2-phenylmethoxycyclopentyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)CC=1C(=O)NC1CCCC1OCC1=CC=CC=C1 VNMYTZXTQQOUCR-UHFFFAOYSA-N 0.000 description 1
- JXLKHGXAKSXEAE-UHFFFAOYSA-N 8-benzylsulfonyl-n-[(2-ethoxyphenyl)methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CCOC1=CC=CC=C1CNC(=O)C(C1)=NOC21CCN(S(=O)(=O)CC=1C=CC=CC=1)CC2 JXLKHGXAKSXEAE-UHFFFAOYSA-N 0.000 description 1
- JWWORDQKRZZQGQ-UHFFFAOYSA-N 8-benzylsulfonyl-n-[2-(3-fluorophenyl)ethyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC1=CC=CC(CCNC(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)CC=2C=CC=CC=2)=C1 JWWORDQKRZZQGQ-UHFFFAOYSA-N 0.000 description 1
- REZWEKFBSWCVEQ-UHFFFAOYSA-N 8-o-tert-butyl 3-o-ethyl 1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3,8-dicarboxylate Chemical compound C1C(C(=O)OCC)=NOC21CCN(C(=O)OC(C)(C)C)CC2 REZWEKFBSWCVEQ-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- ISNYUQWBWALXEY-UHFFFAOYSA-N Batrachotoxin Natural products C=1CC2(C3=CCC4C5(C)CCC(C4)(O)OC53C(O)C3)OCCN(C)CC32C=1C(C)OC(=O)C=1C(C)=CNC=1C ISNYUQWBWALXEY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- YDZBXMYTTXLEOD-UHFFFAOYSA-N COc1ccc(OC)c(CN(Cc2ccco2)C(=O)C2=NOC3(C2)CCN(CC3)S(=O)(=O)c2ccc(F)cc2)c1 Chemical compound COc1ccc(OC)c(CN(Cc2ccco2)C(=O)C2=NOC3(C2)CCN(CC3)S(=O)(=O)c2ccc(F)cc2)c1 YDZBXMYTTXLEOD-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- HDVPYGORGXLEQP-UHFFFAOYSA-N N=1OC2(CCN(CC2)C(=O)C=2C(=CC=CC=2)COC(=O)C=2C=CC=CC=2)CC=1C(=O)NC1CCCC1 Chemical compound N=1OC2(CCN(CC2)C(=O)C=2C(=CC=CC=2)COC(=O)C=2C=CC=CC=2)CC=1C(=O)NC1CCCC1 HDVPYGORGXLEQP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 240000002426 Persea americana var. drymifolia Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- UCXQSWVFCOKWOU-UHFFFAOYSA-N [4-(2,4-dimethylphenyl)piperazin-1-yl]-[8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]methanone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CC2)C=2C(=CC(C)=CC=2)C)CC1 UCXQSWVFCOKWOU-UHFFFAOYSA-N 0.000 description 1
- ALBSZZQKYDPAAS-UHFFFAOYSA-N [4-(2-methylphenyl)piperazin-1-yl]-(8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)methanone Chemical compound CC1=CC=CC=C1N1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC=CC=2)CC1 ALBSZZQKYDPAAS-UHFFFAOYSA-N 0.000 description 1
- JRMWVXYUINGGCV-UHFFFAOYSA-N [4-(3-phenylpropyl)piperazin-1-yl]-(8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl)methanone Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2SC=CC=2)CC=1C(=O)N(CC1)CCN1CCCC1=CC=CC=C1 JRMWVXYUINGGCV-UHFFFAOYSA-N 0.000 description 1
- YDZPTCVWEFNDJF-UHFFFAOYSA-N [8-(4-fluorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-[4-(3-phenylpropyl)piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CCCC=3C=CC=CC=3)CC2)CC1 YDZPTCVWEFNDJF-UHFFFAOYSA-N 0.000 description 1
- VNASIGYPRBRGCV-UHFFFAOYSA-N [8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-(4-phenylpiperazin-1-yl)methanone Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N2CCN(CC2)C=2C=CC=CC=2)CC1 VNASIGYPRBRGCV-UHFFFAOYSA-N 0.000 description 1
- UWIFJCSELWLYCR-UHFFFAOYSA-N [8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-[4-(2-methoxyphenyl)piperidin-1-yl]methanone Chemical compound COC1=CC=CC=C1C1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC(Cl)=CC=2)CC1 UWIFJCSELWLYCR-UHFFFAOYSA-N 0.000 description 1
- UGBLCFMGVHAULC-UHFFFAOYSA-N [8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC(Cl)=CC=2)=C1 UGBLCFMGVHAULC-UHFFFAOYSA-N 0.000 description 1
- ZASBNWDTKWGSDB-UHFFFAOYSA-N [8-(5-chlorothiophen-2-yl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl]-[4-(4-fluorophenyl)piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2SC(Cl)=CC=2)CC1 ZASBNWDTKWGSDB-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KGGODVNXMMAXAK-UHFFFAOYSA-N ethene;hexane Chemical compound C=C.C=C.CCCCCC KGGODVNXMMAXAK-UHFFFAOYSA-N 0.000 description 1
- UXOLDCOJRAMLTQ-UTCJRWHESA-N ethyl (2z)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N\O UXOLDCOJRAMLTQ-UTCJRWHESA-N 0.000 description 1
- HEAHMNRQXQJOAW-UHFFFAOYSA-N ethyl 2-[(8-benzylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl)amino]acetate Chemical compound C(C)OC(CNC(=O)C1=NOC2(C1)CCN(CC2)S(=O)(=O)CC1=CC=CC=C1)=O HEAHMNRQXQJOAW-UHFFFAOYSA-N 0.000 description 1
- IMTIKNTWYJXXEZ-UHFFFAOYSA-N ethyl 2-[[8-(2-ethoxybenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]acetate Chemical compound C1C(C(=O)NCC(=O)OCC)=NOC21CCN(C(=O)C=1C(=CC=CC=1)OCC)CC2 IMTIKNTWYJXXEZ-UHFFFAOYSA-N 0.000 description 1
- HYSZZLXDYIPRBX-UHFFFAOYSA-N ethyl 2-[[8-(3-chlorothiophene-2-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]acetate Chemical compound C1C(C(=O)NCC(=O)OCC)=NOC21CCN(C(=O)C1=C(C=CS1)Cl)CC2 HYSZZLXDYIPRBX-UHFFFAOYSA-N 0.000 description 1
- BAWOPIFGTFSDSZ-UHFFFAOYSA-N ethyl 3-[[8-(6-chloro-2-fluoro-3-methylbenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]propanoate Chemical compound C1C(C(=O)NCCC(=O)OCC)=NOC21CCN(C(=O)C=1C(=C(C)C=CC=1Cl)F)CC2 BAWOPIFGTFSDSZ-UHFFFAOYSA-N 0.000 description 1
- NRUIVUXEUGPCOM-UHFFFAOYSA-N ethyl 4-[(8-butanoyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)CCC)CCC11ON=C(C(=O)NC2CCN(CC2)C(=O)OCC)C1 NRUIVUXEUGPCOM-UHFFFAOYSA-N 0.000 description 1
- YXNIZCBOOCMVOM-UHFFFAOYSA-N ethyl 4-[[8-(2,4-difluorobenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C(C1)=NOC21CCN(C(=O)C=1C(=CC(F)=CC=1)F)CC2 YXNIZCBOOCMVOM-UHFFFAOYSA-N 0.000 description 1
- RVKFROKWDUZFMA-UHFFFAOYSA-N ethyl 4-[[8-(2-phenylcyclopropanecarbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C(C1)=NOC21CCN(C(=O)C1C(C1)C=1C=CC=CC=1)CC2 RVKFROKWDUZFMA-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XWWLMPDAHBDPRQ-UHFFFAOYSA-N methyl 2-[[3-(2-methylpropylcarbamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]sulfonyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC(C)C)CC1 XWWLMPDAHBDPRQ-UHFFFAOYSA-N 0.000 description 1
- NCWCFBWWORYPBQ-UHFFFAOYSA-N methyl 3-(4-chlorophenyl)-2-[[8-(4-methoxyphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]propanoate Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2C=CC(OC)=CC=2)CC=1C(=O)NC(C(=O)OC)CC1=CC=C(Cl)C=C1 NCWCFBWWORYPBQ-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- XYEVWZKPSZNBBI-UHFFFAOYSA-N n-(1-phenylethyl)-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=CS1 XYEVWZKPSZNBBI-UHFFFAOYSA-N 0.000 description 1
- GKFXHWGCVMNZHA-UHFFFAOYSA-N n-(2-acetamidoethyl)-8-(5-fluoro-2-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCNC(=O)C)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(F)C=1)C)CC2 GKFXHWGCVMNZHA-UHFFFAOYSA-N 0.000 description 1
- VFVNVSZERYXMMN-UHFFFAOYSA-N n-(2-cyanoethyl)-8-(2,5-dichlorophenyl)sulfonyl-n-(pyridin-3-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)N(CCC#N)CC=3C=NC=CC=3)CC2)=C1 VFVNVSZERYXMMN-UHFFFAOYSA-N 0.000 description 1
- CUKJYDVYMXQFIR-UHFFFAOYSA-N n-(2-cyanoethyl)-8-[3-(dimethylamino)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound CN(C)C1=CC=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCCC#N)CC2)=C1 CUKJYDVYMXQFIR-UHFFFAOYSA-N 0.000 description 1
- MVWWRUOUDFPQQN-UHFFFAOYSA-N n-(2-phenylmethoxycyclopentyl)-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2SC=CC=2)CC=1C(=O)NC1CCCC1OCC1=CC=CC=C1 MVWWRUOUDFPQQN-UHFFFAOYSA-N 0.000 description 1
- LSXMGEFWZAFQAA-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-(2,3-dichlorobenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCC3CC3)CC2)=C1Cl LSXMGEFWZAFQAA-UHFFFAOYSA-N 0.000 description 1
- VEXPYSDSPCOHDO-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-(2,3-difluoro-4-methylbenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC1=C(F)C(C)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC2CC2)CC1 VEXPYSDSPCOHDO-UHFFFAOYSA-N 0.000 description 1
- QHTLXCKWSUDQII-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-(2-phenoxypropanoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CC2(ON=C(C2)C(=O)NCC2CC2)CCN1C(=O)C(C)OC1=CC=CC=C1 QHTLXCKWSUDQII-UHFFFAOYSA-N 0.000 description 1
- YRBXTHFHCAUXLJ-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-(4-phenoxybutanoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CC2(ON=C(C2)C(=O)NCC2CC2)CCN1C(=O)CCCOC1=CC=CC=C1 YRBXTHFHCAUXLJ-UHFFFAOYSA-N 0.000 description 1
- KJRVWAJSEBMQAX-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-[4-(trifluoromethoxy)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC2CC2)CC1 KJRVWAJSEBMQAX-UHFFFAOYSA-N 0.000 description 1
- WNVHAWDFKBZINF-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-[4-(trifluoromethyl)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC2CC2)CC1 WNVHAWDFKBZINF-UHFFFAOYSA-N 0.000 description 1
- AMDKZKKTVGKAAB-UHFFFAOYSA-N n-(cyclopropylmethyl)-8-hexanoyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(C(=O)CCCCC)CCC11ON=C(C(=O)NCC2CC2)C1 AMDKZKKTVGKAAB-UHFFFAOYSA-N 0.000 description 1
- PZABPPGAWGDQLQ-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)-8-[4-(trifluoromethoxy)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=CN=CC=2)CC1 PZABPPGAWGDQLQ-UHFFFAOYSA-N 0.000 description 1
- GMAMOWAQIDATAV-UHFFFAOYSA-N n-(thiophen-2-ylmethyl)-8-[4-(trifluoromethylsulfanyl)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(SC(F)(F)F)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2SC=CC=2)CC1 GMAMOWAQIDATAV-UHFFFAOYSA-N 0.000 description 1
- PDKUJMZDOVAMBJ-UHFFFAOYSA-N n-[(2,4-difluorophenyl)methyl]-8-(dimethylsulfamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)NCC=2C(=CC(F)=CC=2)F)C1 PDKUJMZDOVAMBJ-UHFFFAOYSA-N 0.000 description 1
- AJGRXEQLVFVNMR-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=C(Cl)C=C(Cl)C=2)CC1 AJGRXEQLVFVNMR-UHFFFAOYSA-N 0.000 description 1
- ICTDLMKLURBMSA-UHFFFAOYSA-N n-[(3-methoxyphenyl)methyl]-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound COC1=CC=CC(CNC(=O)C=2CC3(ON=2)CCN(CC3)S(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 ICTDLMKLURBMSA-UHFFFAOYSA-N 0.000 description 1
- RUZNHFBPFSZGEC-UHFFFAOYSA-N n-[1-(4-chlorophenyl)propan-2-yl]-8-(4-methoxyphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NC(C)CC=2C=CC(Cl)=CC=2)CC1 RUZNHFBPFSZGEC-UHFFFAOYSA-N 0.000 description 1
- LBNFKDCMOLUJEJ-UHFFFAOYSA-N n-[1-(4-methylphenyl)ethyl]-8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=C(C)C=CC=1C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=C(C)C=C1 LBNFKDCMOLUJEJ-UHFFFAOYSA-N 0.000 description 1
- MAZOWNWPQIRYMC-UHFFFAOYSA-N n-[1-(4-methylphenyl)ethyl]-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C=1C=C(C)C=CC=1C(C)NC(=O)C(C1)=NOC1(CC1)CCN1S(=O)(=O)C1=CC=CS1 MAZOWNWPQIRYMC-UHFFFAOYSA-N 0.000 description 1
- UVPHIWXUWOXDCC-UHFFFAOYSA-N n-[2-(3,4-dichlorophenyl)ethyl]-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)NCCC=2C=C(Cl)C(Cl)=CC=2)CC1 UVPHIWXUWOXDCC-UHFFFAOYSA-N 0.000 description 1
- RZLWUIACDVEZDK-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1CCNC(=O)C(C1)=NOC21CCN(S(=O)(=O)C=1SC=CC=1)CC2 RZLWUIACDVEZDK-UHFFFAOYSA-N 0.000 description 1
- MTBYYYYPOZGFGO-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-8-(2-methyl-5-nitrophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCN(C)C)=NOC21CCN(S(=O)(=O)C=1C(=CC=C(C=1)[N+]([O-])=O)C)CC2 MTBYYYYPOZGFGO-UHFFFAOYSA-N 0.000 description 1
- WKBWFENHXDCIGM-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-8-(4-methylphenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1C(C(=O)NCCN(C)C)=NOC21CCN(S(=O)(=O)C=1C=CC(C)=CC=1)CC2 WKBWFENHXDCIGM-UHFFFAOYSA-N 0.000 description 1
- BUZBWEFYJOITKZ-UHFFFAOYSA-N n-benzyl-8-(2,5-dichlorophenyl)sulfonyl-n-(2-phenylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=C(Cl)C(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)N(CCC=3C=CC=CC=3)CC=3C=CC=CC=3)CC2)=C1 BUZBWEFYJOITKZ-UHFFFAOYSA-N 0.000 description 1
- GCCUYXOOZYAYAS-UHFFFAOYSA-N n-benzyl-8-(2-phenoxypropanoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1CC2(ON=C(C2)C(=O)NCC=2C=CC=CC=2)CCN1C(=O)C(C)OC1=CC=CC=C1 GCCUYXOOZYAYAS-UHFFFAOYSA-N 0.000 description 1
- HWLDJRZQSYTHEK-UHFFFAOYSA-N n-benzyl-8-(3-chlorophenyl)sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(S(=O)(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=CC=CC=3)CC2)=C1 HWLDJRZQSYTHEK-UHFFFAOYSA-N 0.000 description 1
- SRBLSCNYDHWNCT-UHFFFAOYSA-N n-benzyl-8-(4-bromobenzoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(Br)=CC=C1C(=O)N1CCC2(ON=C(C2)C(=O)NCC=2C=CC=CC=2)CC1 SRBLSCNYDHWNCT-UHFFFAOYSA-N 0.000 description 1
- NJIRHCKFOWKKFE-UHFFFAOYSA-N n-benzyl-8-(4-methylphenyl)sulfonyl-n-(2-phenylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N(CCC=2C=CC=CC=2)CC=2C=CC=CC=2)CC1 NJIRHCKFOWKKFE-UHFFFAOYSA-N 0.000 description 1
- LBZIYXKRWNRJBI-UHFFFAOYSA-N n-benzyl-8-(pyridine-4-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)C(=O)C=2C=CN=CC=2)CC=1C(=O)NCC1=CC=CC=C1 LBZIYXKRWNRJBI-UHFFFAOYSA-N 0.000 description 1
- HBTLDBXXZJJKKF-UHFFFAOYSA-N n-benzyl-8-[2-(3-chlorophenoxy)acetyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound ClC1=CC=CC(OCC(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=CC=CC=3)CC2)=C1 HBTLDBXXZJJKKF-UHFFFAOYSA-N 0.000 description 1
- VIGDISKOKGHKAN-UHFFFAOYSA-N n-benzyl-8-[3-(difluoromethylsulfanyl)benzoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound FC(F)SC1=CC=CC(C(=O)N2CCC3(ON=C(C3)C(=O)NCC=3C=CC=CC=3)CC2)=C1 VIGDISKOKGHKAN-UHFFFAOYSA-N 0.000 description 1
- TYDWHYYPLIRKKM-UHFFFAOYSA-N n-benzyl-8-thiophen-2-ylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2SC=CC=2)CC=1C(=O)NCC1=CC=CC=C1 TYDWHYYPLIRKKM-UHFFFAOYSA-N 0.000 description 1
- GKGDPPVHLCOMSB-UHFFFAOYSA-N n-benzyl-n-(2-phenylethyl)-8-[4-(trifluoromethoxy)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)N1CCC2(ON=C(C2)C(=O)N(CCC=2C=CC=CC=2)CC=2C=CC=CC=2)CC1 GKGDPPVHLCOMSB-UHFFFAOYSA-N 0.000 description 1
- VKKZXTAHCROGPA-UHFFFAOYSA-N n-cyclopentyl-8-(2-phenoxypyridine-3-carbonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)C(=O)C=2C(=NC=CC=2)OC=2C=CC=CC=2)CC=1C(=O)NC1CCCC1 VKKZXTAHCROGPA-UHFFFAOYSA-N 0.000 description 1
- YYJGRUULSKAJHF-UHFFFAOYSA-N n-methyl-n-(pyridin-3-ylmethyl)-8-[3-(trifluoromethyl)phenyl]sulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carboxamide Chemical compound N=1OC2(CCN(CC2)S(=O)(=O)C=2C=C(C=CC=2)C(F)(F)F)CC=1C(=O)N(C)CC1=CC=CN=C1 YYJGRUULSKAJHF-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- TYJHEKQAXGPVQO-UHFFFAOYSA-N tert-butyl 2-[[8-(dimethylsulfamoyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-3-carbonyl]amino]-3-phenylpropanoate Chemical compound C1CN(S(=O)(=O)N(C)C)CCC11ON=C(C(=O)NC(CC=2C=CC=CC=2)C(=O)OC(C)(C)C)C1 TYJHEKQAXGPVQO-UHFFFAOYSA-N 0.000 description 1
- VYSOWHWNZAUJMR-YMBRHYMPSA-N tert-butyl 3-[[(1R)-2-phenylmethoxycyclopentyl]carbamoyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC2(CC(=NO2)C(N[C@H]2C(CCC2)OCC2=CC=CC=C2)=O)CC1 VYSOWHWNZAUJMR-YMBRHYMPSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000000179 transient infrared spectroscopy Methods 0.000 description 1
- ISNYUQWBWALXEY-OMIQOYQYSA-N tsg6xhx09r Chemical compound O([C@@H](C)C=1[C@@]23CN(C)CCO[C@]3(C3=CC[C@H]4[C@]5(C)CC[C@@](C4)(O)O[C@@]53[C@H](O)C2)CC=1)C(=O)C=1C(C)=CNC=1C ISNYUQWBWALXEY-OMIQOYQYSA-N 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Sammendrag Det er beskrevet substituerte l-oksa-2,8-diazaspiro[4.5]dec-en-derivater av generell formel (I) samt fremgangsmåte for deres fremstilling, deres anvendelse for fremstilling av legemidler og legemidler inneholdende disse forbindelsene.
Description
Foreliggende oppfinnelse vedrører substituerte l-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater, samt fremgangsmåter for deres fremstilling, deres anvendelse for fremstilling av legemidler og legemidler inneholdende disse forbindelsene.
Behandlingen av kroniske og ikke-kroniske smertetilstander har en stor betydning innenfor medisinen. Det foreligger et verdensomspennende behov for godt virksomme smertebehandlinger for en pasientgodtagbar og målorientert behandling av kroniske og ikke-kroniske smertetilstander, hvorved det herunder er å forstå vellykket og tilfredsstillende behandling for pasientene. Dette viser seg i det store antallet vitenskapelige arbeider som er publisert innenfor området anvendt analgetikk,
henholdsvis grunnforskning vedrørende nocisepsjon i den senere tiden.
Klassiske opioider, som morfin, er godt virksomme ved behandling av sterke til meget sterke smerter. Deres anvendelse begrenses imidlertid ved de kjente bivirkningene, for eksempel åndedrettsundertrykkelse, brekninger, sedering, obstipasjon og toleranseutvikling. Videre er de mindre virksomme ved neuropatiske eller insidensielle smerter, som blant annet tumorpasienter lider av.
Opioider utfolder sin analgetiske virkning ved binding til membranstående reseptorer,
som hører til familien av såkalte g-proteinkoblede reseptorer. Den biokjemiske og farmakologiske karakteirseringen av undertyper av disse reseptorene har nå vekket håp om at subtypen spesifikke opioider skal ha en annen virknings-/bivirkningsprofil enn for eksempel morfin. Ytterligere farmakologiske undersøkelser har i mellomtiden sansynliggjort eksistensen av flere subtyper av disse opioidreseptorene (ui,U2,X2>X3>81og 82).
I tillegg finnes det ytterligere reseptorionekanaler som i vesentlig grad er delaktige i systemet med smerteoppståelse og smertevidereføring, eksempelvis det såkalte batrakotoksin (BTX)bindingssetet (=bindingssete 2) av natriumkanalen eller NMDA-ionekanalen, over hvilken den vesentlige delen av kommunikasjonen av synapser ved styring av kalsiumionebyttingen mellom neuronale celler og deres omgivelser forløper.
Til grunn for foreliggende oppfinnelse ligger som en oppgave å tilveiebringe analgetisk virksomme forbindelser som egner seg for smertebehandling - eventuelt også for behandling av kroniske og neuropatiske smerter. Videre skal disse stoffene ønskelig ikke oppvise bivirkninger eller bare i liten grad de bivirkningene som vanligvis opptrer ved anvendelsen av opioider som morfin, som for eksempel uvelhet, brekninger, avhengighet, åndedrettsundertrykkelse eller obstipasjon.
Oppgaven løses ved de analgetisk virksomme substituerte l-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivatene med generell formel (I)
eventuelt i form av dens racemater, deres rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av deres syrer eller deres baser eller i form av deres salter eller solvater;
hvori
R1 og R2 uavhengig av hverandre betyr H, Ci-Cig-alkyl, C3-Cio-cykloalkyl, (C1-12-alkyl)-C3-io-cykloalkyl, aryl (Ci-i2-alkyl)-aryl, heterocyklyl eller NH-C(=0)-aryl, hvorved minst en av restene R<1>og R2 ikke betyr H,
eller
står sammen for-(CR<4>R<5>)m-(CR<6>R<7>)n-Y-(CR<8>R9)p-(CR<I0>R<n>)q- med m, n, p og q i hvert tilfelle = 0, 1, 2, 3, 4 eller 5, under den forutsetningen at
m+n > 1 og p+q > 1, eller står for -CH2-CH2-C(-aryl)=CH-CH2-;
R<3>betyr H, S02R<12>eller COR<13>;
R<4>, R<5>, R<6>,
R<7>, R<8>, R<9>,
R<10>og R<11>står uavhengig av hverandre for H, Ci-io-alkyl, C3-g-cykloalkyl, (Ci-6-alkyl)-C3.8-cykloalkyl, aryl, (Ci.6-alkyl)-aryl, heterocykyl, (Ci.6-alkyl)-heterocyklyl eller betyr C(=0)R<14>;
Y betyr CR<15>R<16>, NR<17>eller O;
R<12>og R<13>betyr uavhengig av hverandre Ci-io-alkyl, C3-io-cykloalkyl, (Ci-6-alkyl)-C3-io-cykloalkyl, aryl, (Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller NRI8R19;
R<14>betyr H, Q-io-alkyl, C3.8-cykloalkyl, (Ci.6-alkyl)-C3.8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller OR<20>;
R1<5>og R<16>betyr uavhengig av hverandre H, Ci-io-alkyl, C3-g-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl, (Ci^-alkyl)-heterocyklyl eller C(=0)R<21>;
R<17>betyr H, Ci-io-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller C(=0)R<22>;
R<18>og R<19>betyr uavhengig av hverandre H, Q-io-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl eller (Ci-6-alkyl)-heterocyklyl;
R20betyr H, Ci-io-alkyl, C^-cykloalkyl, (Ci.6-alkyl)-C3.8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl eller (Ci^-alkyl)-heterocyklyl;
R<21>betyr H, Ci-io-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller OR<23>;
R<22>betyr H, Ci-io-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci-6-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller OR24og
R<2>3ogR2<4>betyr uavhengig av hverandre H, Ci-io-alkyl, C3_8-cykloalkyl, (Ci_6-alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl eller (Ci-6-alkyl)-heterocyklyl;
hvori aryl betyr en rest valgt fra gruppen bestående av fenyl, naftyl, fenantrenyl, antracenyl, og bifenyl, eventuelt substituert med Ci^-alkyl, F, Cl, Br, I, CF3, O-Ci-6-alkyl, OCF3, fenyl, CN og N02; og
heterocyclyl betyr en rest valgt fra gruppen bestående av pyrrolidinyl, tetrahydrofuryl, 1,4-dioksanyl, piperidinyl, piperazinyl og morfolinyl, eventuelt substituert med C1-6-alkyl, F, Cl, Br, I, CF3, 0-CM-alkyl, OCF3, fenyl, CN og N02,
hvor alkyl eventuelt er substituert med F, Cl, Br, CN, NH2, NH-alkyl, NH-aryl, NH-alkyl-aryl, NH-heterocyklyl, N(alkyl)2, N(alkyl-aryl)2, N-alkyl-N-aryl, N02, OH, O-alkyl, S-alkyl, O-aryl, O-alkyl-aryl, O-alkyl-O-alkyl, C(=0)-Ci.6-alkyl, C(=0)-aryl, C(=0)-Ci-6-alkyl-aryl, C(=0)-heterocyklyl, C02H, C02-alkyl-aryl, C(=0)NH2, C(=0)NH-alkyl, C(=0)NH-aryl, C(=0)NH-heterocyklyl, C(=0)N(alkyl)2, C(=0)N(alkyl-aryl)2, cykloalkyl, aryl eller heterocyklyl,
hvori
alkyl er valgt fra gruppen bestående av metyl, etyl, n-propyl, n-butyl, iso-butyl, sek-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-heksyl, 2-heksyl, n-heptyl, n-oktyl, n-nonyl, n-decyl, n-dodecyl, etenyl (vinyl), etinyl, propenyl, (-CH2CH=CH2,-CH=CH-CH3,-C(=CH2)-CH3), propinyl (-CH2-CeCH,-CeC-CH3) og butenyl;
cykloalkyl er valgt fra cyklopropyl, cyklobutyl, cyklopentyl, cyckloheksyl, cykloheptanyl, cyklooktanyl, adamantanyl og bicyklo[3.1.1]heptan-3-yl;
aryl er valgt fra gruppen bestående av fenyl, naftyl, fenantrenyl, antracenyl og bifenyl; og
heterocyklyl er valgt fra gruppen bestående av pyrrolidinyl, tetrahydrofuryl, 1,4-dioksanyl, piperidinyl, piperazinyl, morfolinyl, pyrrolyl, furanyl, tienyl, pyrazolyl, imidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoksazolyl, tieno[2,3-d]pyrimidinyl, indolyl og pyridinyl.
Disse forbindelsene med generell formel (I) ifølge oppfinnelsen har vist seg som analgetisk virksomme forbindelser. De kan binde til BTX-bindingssete av natriumkanalen, henholdsvis er de NMDA-antagonister med analgetisk virkning.
Uttrykkene "(CM2-alkyl)-C3-io-cykloalkyl", "(Ci^-alkyl)-C3-i0-cykloalkyl", "(C1-4-alkyl)-C3.10-cykloalkyl", "(C1.3-alkyl)-C3.10-cykloalkyl", "(C^ralky^-heterocyklyl", "(Ci-6-alkyl)-heterocyklyl", "(Ci^-alkyl)-heterocyklyl", "(Ci.3-alkyl)-heterocyklyl", "(Ci-i2-alkyl)-aryl", "(Ci^-alkyl)-aryl", "(CM-alkyl)-aryl" og "(Ci.3-alkyl)-aryl" betyr i forbindelse med foreliggende forbindelse at cykloalkyl-, heterocyklyl-, henholdsvis arylresten er bundet over en C1-12-, C1-6-, C1-4-, henholdsvis Ci-3-alkylgruppe til den med denne substituerte forbindelsen. Et spesielt foretrukket eksempel på "alkyl-cykloalkyl" er cyklopropylmetylresten.
Flersubstitusjonen kan foregå med samme eller med forskjellige substituenter. Spesielt foretrukket for formålene med foreliggende oppfinnelse er CF3som substituert alkyl.
"Benzokondensert" betyr for formålene med foreliggende oppfinnelse at en benzenring kan være påkondensert på en annen syklus.
Farmasøytisk godtagbare, henholdsvis fyriologisk godtagbare, salter i forbindelse med foreliggende oppfinnelse er slike salter av forbindelsene med formel (I) ifølge oppfinnelsen som ved farmasøytisk anvendelse er fysiologisk godtakbare- spesielt ved anvendelsen på pattedyr og/eller mennesker -det vil si ikke fremkaller noen (akutte) vesentlig påvirkning av de fysiologiske funksjonene for de aktuelle spesis. Slike farmasøytisk godtakbare (fysiologisk godtakbare) salter kan eksempelvis dannes med uorganiske eller organiske syrer, eller for det tilfellet at forbindelsene ifølge oppfinnelsen er syrer, spesielt karboksylsyrer, med baser.
Fortrinnsvis dannes de farmasøytisk godtakbare saltene av forbindelser ifølge oppfinnelsen med generell formel (I) med saltsyre, bromhydrogensyre, svovelsyre, fosforsyre, metansulfonsyre, p-toluensulfonsyre, karboksylsyre, maursyre, edikksyre, oksalsyre, ravsyre, vinsyre, mandelsyre, fumarsyre, melkesyre, sitronsyre, glutaminsyre eller asparaginsyre. Dreier det seg ved forbindelsen ifølge oppfinnelsen om syrer, for eksempel karboksylsyrer, kan de farmasøytisk godtagbare saltene dannes ved omsetning med baser, som for eksempel natriumhydroksid, natriumhydrogenkarbonat eller natriumkarbonat. Ved de dannede saltene dreier det seg blant annet om hydroklorider, hydrobromider, fosfater, karbonater, hydrogenkarbonater, formiater, acetater, oksalater, suksinater, tartrater, fumarater, sitrater og glutaminater av forbindelsen ifølge oppfinnelsen, som for eksempel kan oppnås ved krystallisasjon fra vandig oppløsning.
Dersom forbindelsene med formel (I) ifølge oppfinnelsen inneholder minst ett asymmetirsentrum, kan de foreligge i form av deres racemater, i form av de rene enantiomerene og/eller (i tilfelle flere asymmetrisentere) diastereomerene eller i form av blandinger av disse enantiomerene, henholdsvis diastereomerene, og nærmere bestemt så vel i stoff som også fysiologisk godtagbare salter av disse forbindelsene. Blandingene kan foreligge i et hvilket som helst blandingsforhold av stereoisomerene. Fortrinnsvis foreligger forbindelsene med generell struktur (I) som enantiomerrene forbindelser.
Foretrukne forbindelser med generell formel (I) ifølge oppfinnelsen er slike som er kjennetegnet ved at
R<1>og R<2>uavhengig av hverandre betyr H, Ci-g-alkyl, C3-g-cykloalkyl, (Ci.
4-alkyl)-C3-8-cykloalkyl, aryl, (CM-alkyl)-aryl, heterocyklyl, (Ci.4-alkyl)-heterocyklyl eller NH-C-(=0)-aryl, hvorved minst en av restene R<1>og R2 ikke betyr H,
eller
står sammen for -(CR<4>R<5>)m-(CR<6>R<7>)n-Y-(CR<8>R<9>)p-(CR<I>0Rn)q-med m=l, n=0 eller 1, p=l eller 2 og q=l eller 2, eller står for - CH2-CH2-C(-aryl)=CH-CH2-;
R<3>betyr S02R<12>eller COR<13>;
R<4><lj5><p6>p7 p8
, IV , IV , IV , IV ,
R<9>,R10og R<11>betyr uavhengig av hverandre H, Ci-g-alkyl eller C(=0)R<14>;
Y betyr CR<I5>R<16>eller NR<17>;
R12betyr Ci^-alkyl, (Ci^-alkyl)-C3-g-cykloalkyl, aryl, (Ci^-alkyl)-aryl, heterocyklyl eller NRI8R<19>;
R<13>Ci-6-alkyl, C3-io-cykloalkyl, aryl, (d^-alkyl)-aryl eller heterocyklyl;
R<14>betyr OR<20>;
R<15>og R<16>betyr uavhengig av hverandre H, aryl eller (Ci^-alkyl)-aryl;
R17betyr H, C3-g-cykloalkyl, aryl, (CM-alkyl)-aryl, heterocyklyl eller
C(=0)R<22>;
R<18>og R<19>betyr uavhengig av hverandre H eller Ci-6-alkyl;
R<20>betyr Ci.6-alkyl;
R<22>betyr aryl, (CM-alkyl)-aryl, heterocyklyl eller OR24;og
R<24>Ci-e-alkyl eller (Ci-4-alkyl)-aryl.
En spesielt foretrukket undergruppe av disse foretrukne forbindelsen av formel (I) utgjøres av forbindelse hvori
R<1>betyr Ci-e-alkyl, C3.8-cykloalkyl, (Ci-3-altyl)-C3-8-cykloalkyl,
aryl, (Ci-3-alkyl)-aryl, heterocyklyl, (Ci-3-alkyl)-heterocyklyl eller NH-C(=0)-aryl; og
R<2>betyr H, C^-alkyl, (Ci-3-alkyl)-aryl eller (Ci.3-alkyl)-heterocyklyl;
hvorved helt spesielt foretrukne forbindelser er slike hvori
R<1>betyr usubstituert eller med F, Cl, Br, I, -CN, N-d-6-alkyl-N-arylamin, N,N-dialkylamin, amid, karboksylalkyl, karboksybenzyl, substituert metyl, etyl, n-propyl, iso-propyl, 2-metylpropyl, n-butyl, tert-butyl, n-pentyl, 3-metylbutyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl, CH2-C(CH3)=CH2, CH(C(=0)OCH2CH=CH2)-CH2C(=0)0-tert-butyl, 2-cyanoetyl, CH2-CH2-NH-C(=0)CH3, 2-(N-etyl-N-(3-metylfenyl)amino)-etyl, 2-(N,N-dimetylamino)-etyl, 2-(C(=0)-NH-((5-naftyl)-etyl, 1,2-(di-(C(=0)0-tert-butyl)etyl, 3-(N-metyl-N-fenylamino)-propyl, l-(C(=0)0-benzyl)-3-metyl-butyl, l-(C(=0)0-butyl)-3-metyl-butyl, CH2C02etyl, CH2-CH2C02etyl, CH2-CH2-Ofenyl, CH2-CH2-S-CH2-CH3;
usubstituert eller med F, Cl, Br, I, -CN, Ci-6-alkyl, aryl, karboksylalkyl, karboksybenzyl, O- C1-6- alkyl, O-benzyl substituert cyklopropyl, cyklobutyl, cyklopentyl, cykloheksyl, cykloheptyl, cyklooktyl, bicyklo[3.1.1]heptan-3-yl, spesielt 2-fenylcylopropyl, 2-(0-benzyl)-cyklopentyl, 2-(karboksyletyl)cykloheksyl, 7,7-dimetyl-2-(karboksyetyl)cykloheksyl, 7,7-dimetyl-2-
metylbicyklo[3.1.1]heptan-3-yl; cyklopropylmetyl, 7,7-dimetyl-2-okso-bicyklo[2.2. l]hept- 1-ylmetyl;
usubstituert eller med fenoksy, -CH2-P (=0)(Oetyl)2substituert fenyl, 1-naftyl eller 2-naftyl; CH2-aryl, CH2-CH2-aryl, CH2-CH2-CH2-aryl, CH2-CH2-CH2-CH2-aryl CH(CH3)-aryl, CH(CH3)-CH2-aryl, CH2-CH-(aryl)2, CH(C02alkyl)-CH2-aryl, CH2-CH2-CH-(aryl)2, hvorved aryl er usubstituert fenyl, 1-naftyl eller 2-naftyl eller med F, Cl, Br, I, -CN, -N02, alkyl, CF3, alkoksy, alkylendioksy, substituert fenyl, spesielt benzyl, -CH2-naft-l-yl, 2- fluorbenzyl, 3-fluorbenzyl, 3-klorbenzyl, 3-metoksybenzyl, 2-etoksybenzyl, 2,4-difluorbenzyl, 3,5-diklorbenzyl, 3-fluor-5-trifluormetylbenzyl, 3-fluor-4-trifluormetylbenzyl, 2-klor-6-fluorbenzyl, 2,5-dimetoksybenzyl, 2-klor-6-metyl-benzyl, 3,4-dimetoksybenzyl, 3,4-dioksymetylenbenzyl, CH(CH3)-fenyl, CH(CH3)-(4-CH3-fenyl), CH(CH3)-(4-nitrofenyl), CH(CH3)-(2,3-dioksyetylenfenyl), CH2-CH2-fenyl, CH2-CH2-(2-fluorfenyl), CH2-CH2-(3-fluorfenyl), CH2-CH2-(4-fluorfenyl), CH2-CH2-(4-klorfenyl), CH2-CH2-(3,4-diklorfenyl), CH2-CH2-(3-metoksyfenyl), CH2-CH2-(2,5-dimetoksyfenyl), CH(C02-tert-butyl)-CH2-fenyl, CH(C02-metyl)-CH2-(4-klorfenyl), CH2-CH(fenyl)2, CH(CH3)-CH2-(4-klorfenyl), CH2-CH2-CH(fenyl)2, CH2, CH2-CH2-fenyl;
usubstituert eller med aryl, alkylaryl eller karboksyetyl substituert pyrrolidin eller piperidin, spesielt pyrrolidin-3-yl, N-(4-trifluorbenzyl)-pyrrolidin-3-yl, N-(3-metoksybenzyl)-pyrrolidin-3- yl, N-(CH2-(p-naftyl)-pyrrolidin-3-yl eller N-(karboksyetyl)-piperidin-4-yl; usubstituert eller med alkyl, F, Cl, Br, I, -CN, aryl, alkylaryl, substituert (CH2)i_3-heterocyklyl, hvorved heterocyklyl står for furanyl, benzofuranyl, 1,4-dioksanyl, benzo-1,4-dioksanyl, tienyl, pyridinyl, pyrrolidinyl, lH-indolyl, imidazolyl, piperidinyl, tetrahydrofuranyl, spesielt, CH2-furan-2-yl, 5-metylfuran-2-yl CH2-benzofuran-2-yl,
CH2-tien-2-yl, CH2-pyridin-3-yl, CH2-pyridin-4-yl, CH2-CH2-pyridin-2-yl, CH2-CH2-(lH-indol-3-yl), CH2-CH2-pyrrolidin-l-yl, CH2-(N-2,6-diklorbenzylpyrrolidin-3-yl), CH2-CH2-(N-metyl-pyrrolidin-2-yl), -CH2)3-imidazol-l-yl, CH2-(tetrahydrofuran-2-yl) eller -H2C-H2C-H2C
, eller CH(C02metyl)-CH2-(lH-
indol-3-yl);
NH-C(=0)-(4-dietylaminofenyl); og
R<2>står for H;
usubstituert, eller med F, Cl, Br, I, -CN substituert metyl, etyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl, 2-cyanoetyl, CH2-C(CH3)<=>CH2;
usubstituert, eller med F, Cl, Br, I, -CN, metoksy, etoksy, substituert benzyl eller fenetyl, spesielt benzyl, 4-fluorbenzyl, 2-klor-6-fluorbenzyl, 2,5-dimetoksybenzyl, fenetyl; eller
CH2-furanyl, spesielt CH2-furan-2-yl, CH2-benzofuranyl, spesielt CH2-benzofuran-2-yl, CH2-pyridinyl, spesielt CH2-pyridin-3-yl, CH2-tetrahydrofuranyl, spesielt CH2-tetrahydrofuran-2-yl, CH2-CH2-pyridinyl, spesielt CH2-CH2-pyridin-2-yl.
En ytterligere gruppe av foretrukne forbindelser med formel (I) ifølge oppfinnelsen utgjøres av slike som er kjennetegnet ved at R<1>og R<2>sammen står for
.hvori aryl betyr
fenyl eller med F, Cl, Br, I substituert fenyl, spesielt 4-fluorfenyl;
R<6>betyr H eller Ci-4-alkyl, spesielt metyl;
R<10>betyr H, C(=0)Ometyl, C(=0)Oetyl, C(=0)0-n-propyl, C(=0)0-iso-propyl, C(=0)0-n-butyl, C(=0)0-tert-butyl;
R<15>betyr H eller CH2-aryl;
R<16>betyr H;
R<17>betyr H;
C3-g-cykloalkyl, spesielt cykloheptyl; aryl, spesielt usubstituert eller med metyl, etyl, n-propyl, iso-propyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, metoksy, etoksy, n-propyl, iso-propoksy, n-butoksy, tert-butoksy substituert fenyl eller naftyl;
((CH2)i-3-alkyl)-aryl eller CH(CH3)-aryl, hvorved aryl betyr usubstituert eller med alkyl, CF3, F, Cl, Br, I, -CN, alkoksy substituert fenyl eller naftyl; usubstituert eller med alkyl, CF3, F, Cl, Br, I, -CN, alkoksy substituert pyridinyl, pyrazinyl eller tieno[2,3-d]pyrimidinyl; eller betyr C(=0)R22;og
R<22>betyr fenyl eller alkoksysubstituert fenyl, O-metyl, O-etyl, O-n-propyl, O-iso-propyl, O-n-butyl, O-tert-butyl, O-benzyl, usubstituert benzyl med F substituert benzyl, usubstituert pyrazinyl eller med alkyl substituert pyrazinyl;
hvorved under disse forbindelsene slike er helt spesielt foretrukne forbindelser hvoriR<6>betyr H eller metyl;
R<10>betyr H eller C(=0)Oetyl;
R<15>betyr H eller benzyl;
R16betyr H; og
R<17>betyr H;
cykloheptyl;
fenyl, 2-metylfenyl, 3-metylfenyl, 2,4-dimetylfenyl, 2-etylfenyl, 3- trifluormetyl, 4-fluorfenyl, 4-klorfenyl, 2-metoksyfenyl, 3,5-dimetoksyfenyl, 3-klor-6-metylfenyl, benzyl, CH2-(4-tert-butylfenyl), CH2-((5-naftyl), CH(CH3)-fenyl, (CH2)3-fenyl;
pyridin-2-yl, (4-trifluormetyl)-pyridin-2-yl, tieno[2,3-d]pyrimidin-4-yl; eller
C(=0)-(4-metoksyfenyl), C(=0)-benzyl, C(=0)-CH2-(3,4-difluorfenyl), C(=0)-(2-metylpyrazin-5-yl), C(=0)0-tert-butyl eller O-benzyl.
Videre er det foretrukket at, når i forbindelsene med generell formel (I) ifølge oppfinnelsen R<3>betyr S02R<12>,
R<12>betyr metyl, etyl, n-propyl, iso-propyl, spesielt n-propyl;
7,7-dimetyl-2-okso-bicyklo[2.2.1]hept-l-ylmetyl; fenyl eller med metyl, etyl, n-propyl, isopropyl, n-butyl-tert-butyl-CF3, F, Cl, Br, I, -CN, NO2, metoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, tert-butoksy, OCF3, C02metyl substituert fenyl, spesielt 4- metylfenyl, 3-trifluormetylfenyl, 4-fluorfenyl, 2-klorfenyl, 3-klorfenyl, 4-klorfenyl, 4-metoksyfenyl, 4-trifluormetoksyfenyl, 4-nitrofenyl, 2-C02metyl-fenyl, 2,5-diklorfenyl, 3-fluor-6-
metylfenyl, 3-brom-6-metoksyfenyl, 2-metyl-5-nitrofenyl, 2,4,6-trimetylfenyl;
benzyl eller med metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, NO2, metoksy, etoksy, n-propoksy, iso-propoksy, n-butoksy, tert-butoksy, OCF3substituert benzyl;
usubstituert eller med metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, NO2, metoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, tert-butoksy substituert furanyl eller tienyl, spesielt tien-2-yl, 5-klortien-2-yl eller NRI8R1<9>; og
R<18>og R<19>betyr uavhengig av hverandre H, metyl eller etyl.
HIT - krav 8
Videre er det foretrukket når, i forbindelsene med generell formel (I) ifølge oppfinnelsenR<3>betyr COR<13>,
R<13>betyr usubstituert eller med O-mety 1, O-etyl, 0-(CH2)2-OCH3,0-benzyl, O-fenyl, hvorved fenyl er usubstituert eller er substituert med F, Cl, Br, I, -CN, 0-C(=0)-metyl, 0-C(=0)-etyl substituert metyl, etyl, C(=0)Ometyl, n-propyl, iso-propyl, 2-metylpropyl, n-butyl, tert-butyl, n-pentyl eller 3-metylbutyl, spesielt metyl, etyl, n-propyl, n-butyl, tert-butyl, n-pentyl, CH2-O-CH2-CH2-OCH3, CH(CH3)-0-fenyl, CH2CH2-C(=0)OCH3, C(CH3)2-OC(=0)CH3, CH2-0-benzyl, CH2-0-(3-klorfenyl), CH2-CH2-CH2-0-fenyl, CH(OC(=0)metyl)CH3; cyklopropyl, 2-fenylcyklopropyl, 1-adamantyl; usubstituert eller med F, Cl, Br, I, -CN, fenyl, metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, - CN, NO2, metoksy, etoksy, n-propoksy, iso-propoksy, n-butoksy, tert-butoksy, OCF3, OCHF2, OCH2F, SCF3, SCHF2, SCH2F, SCH3, CH2OC(=0)fenyl, -N(CH3) substituert fenyl eller naftyl, spesielt 4-fluorfenyl, 2-klorfenyl, 3-klorfenyl, 4-bromfenyl, 4-fenylfenyl (4-bifenyl), 4-etylfenyl, 4-CF3-fenyl, 4-metoksyfenyl, 2-etoksyfenyl, 4-tert-butyl, 3-OCF3-fenyl, 4-OCF3-fenyl, 4-SCF3-fenyl, 3-SCF2-fenyl, 2-CH2-OC(=0)fenyl, 3-dimetylaminofenyl, 2,3-diklorfenyl, 2,4-difluorfenyl, 3-klor-4-fluorfenyl, 3-klor-2-fluorfenyl, 4-CF3-3-fluorfenyl, 3-CF3-6-fluorfenyl, 4-brom-3-metylfenyl, 2-klor-4-nitrofenyl, 2,3,4,5,6-pentafluorfenyl, 2,6- difluor-3-metylfenyl, 2,3-difluor-4-metylfenyl, 2-klor-5-metyl-6-fluorfenyl, 1-naftyl, 2-naftyl;
usubstituert eller substituert (Ci-2-alkyl)-aryl, spesielt benzyl, fenetyl, CH(C2H5)-fenyl, CH(NH-S02-(4-metylfenyl))-CH2-fenyl, CH=CH-fenyl, CH=CH-(3-trifluorfenyl); eller
usubstituert eller alkylsubstituert furanyl, benzofuranyl, usubstituert eller med alkyl, CF3, aryl, O-fenyl, klor, S-metyl, S-etyl substituert tienyl, pyridinyl, pyrazolyl, benzodihydropyranyl, isooksazolyl, spesielt l,5-dimetylfuran-3-yl, 2-metyl-5-tert-butyl-furan-3-yl, 3-klortien-2-yl, l-(4-klorfenyl)-5-trifluormetyl-pyrazol-4-yl, l-metyl-3-
tert-butyl-pyrazol-5-yl, pyridin-4-yl, 2-metyltiopyridin-3-yl, 2-etyltiopyridin-3-yl, 2-fenoksypyridin-3-yl, 2-klorpyridin-3-yl, 5-metyl-3-(2,6-diklorfenyl)-isoksazol-4-yl, 5-metyl-3-(2-klor-6-fluorfenyl)-isoksazol-4-yl.
Utvalgte og spesielt foretrukne forbindelser med formel (I) ifølge oppfinnelsen er: • 3-(lH-indol-3-yl)-2- {[8-(4-trifluormetoksy-benzensulfonyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyremetylester • {4-[(8-fenylmetansulfonyl-1 -oksa-2,8-diaza-sprio[4.5]dec-2-en-3-karbonyl)-amino]-benzyl}-fosfonsyredietylester • (4-cykloheptyl-piperazin-1 -yl)-[8-(tiofen-2-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-fenyl-piperazin-1 -yl)-metanon • 8-(2-klor-4-nitro-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre cyklopentylamid • (4-naftalin-2-ylmetyl-piperazin-1 -yl)-(8-fenylmetansulfonyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenetylamid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(l-fenyl-etyl)-amid • 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-(3,4-diklorfenyl)-etyl]-amid • 4-dietylamino-benzosyre N'-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-hydrazid • 8-(3-klor-4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-pyrrolidin-1 -yl-etyl)-amid • 8-fenylmetansulfonyl- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrepenetyl-amid • 8-benzensulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • [4-(3-fenyl-propyl)-piperazin-l-yl]-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[3-(2-metyl-piperidin-l-yl)-propyl]-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(lH-indol-3-yl)-etyl]-metyl-amid • 8-(5-fluor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-acetylamino-etyl)-amid • 8-(toluen-4-sulfonyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2-metyl-5-nitro-benzensylfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • 8-fenylrnetansulfonyl-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,3-dihydro-benzo[1.4]dioksin-2-ylmetyl)-amid • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(4-fenoksyfenyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(1 -p-tolyl-etyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-benzylamid • 2-fenyl-l-{4-[8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperazin-1 -yl} -etanon • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-
[ 1 -(4-trifluormetyl-benzyl)-pyrrolidiri-3-yl]-arnid • [8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-o-tolyl-piperazin-1 -yl)-metanon • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzyl-(2-cyanoetyl)-amid • [8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-tieno[2,3-d]pyrimidin-4-yl-piperazin-1 -yl)-metanon • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(benzo[ 1.3]dioksol-5-ylmetyl)-amid • (3-me1yl-4-m-tolyl-piperazin-l-yl)-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [4-(l-fenyl-etyl)-piperazin-l-yl]-[8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [4-(2,4-dimetyl-fenyl)-piperazin-1 -yl]- [8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2-klor-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopentylamid • (4-naftalen-2-ylmetyl-piperazin-1 -yl)-[8-(3-trifluormetyl-benzensulfonyl)-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-[3-fenyl-2-(toluen-4-sulfonylamino)-propionyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-3-ylmetyl)-amid • 8-(5-fluor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-sprio[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • 8-(4-nitro-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-5-trifluormetyl-benzylamid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzhydryl-amid • 8-[3-fenyl-2-(toluen-4-sulfonylamino)-propionyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-amid • [(8-fenylrnetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-edikksyreetylester • 8-(3-dimetylamino-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-cyano-etyl)-amid
8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre- [ 1 -(naftalin-2-ylkarbamoyl)-ety l]-amid 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(1 -p-tolyl-etyl)-amid
[4-(4-klor-fenyl)-piperazin-l-yl]-(8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-metanon
8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid
8-acetyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re-2,5 -difluor-benzy lamid
• 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(l-naflalin-2-ylrnetyl-pyrrolidin-3-yl)-arnid • 8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-2-etoksy-benzylamid • 8-(4-etyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-ene-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 2- {[8-(2,5-diklor-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -ravsyre-1 -allylester-4-tert-butylester • 8-(4-trifluormetoksy benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-naftalin-2-ylamid • 4-{[8-(2-fenyl-cyklopropankarbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • 4-{[8-(2,4-difluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-piperidin-l-karboksylsyreetylester • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-dimetylamino-etyl)-amid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre[2-(4-klor-fenyl)-etyl]-amid • 8-(4-metoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(5-me1yl-furan-2-ylrnetyl)-arnid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-etyl]-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-amid • 4-[{[8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino]-piperidin-1 -karboksylsyreetylester • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3,5-diklor-benzy lamid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[l-(3-metoksy-benzyl)-pyrrolidin-3-yl]-amid • 3-(4-naftalin-2-ylmetyl-piperazin-l-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyre dimetylamid • 3- {[8-(7.7-dimetyl-2-okso-bicyklo[2.2.1 ]hept-l -ylmetansulfonyl)- 1-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-(toluen-4-sulfonyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-benzyloksy-cyklopentyl)-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre3,4-dimetoksy-benzylamid • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-[4-(3-fenyl-propyl)-piperazin-1 -yl]-metanon • 3-(4-tieno[2,3-d]pyrimidin-4-yl-piperazin-l-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimety lamid • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(3,5 -dimetoksy- feny l)-piperazin-1 -yl] -metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-4-trifluormetyl-benzylamid • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 4-[(8-butyryl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-piperidin-1 -karboksylsyreetylester • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-kaboksylsyre-(2-fenyl-cyklopropyl)-amid • [8-(4-fluor-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(5-metyl-pyrazin-2 -karbony l)-piperazin-1 -yl] -metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-2,4-difluor-benzylamid • 8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(3-fluor-fenyl)-etyl]-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-ene-3-karboksylsyre-(2,2-difenyl-etyl)-amid • 3-[4-(3-fenyl-propyl)-piperazin-l-karbonyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimety lamid
3-{[8-(3,5-difluor-benzoyl)-l-oksa-2,8-diasa-spiro[4.5]dec-2-en-3-karbony 1] -amino} -propionsyreety lester
8-(propan-1 -sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid
[4-(3-fenyl-propyl)-piperazin-1 -yl]-[8-(3-trifluormetyl-benzensulfonyl)-1 -
oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon
8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[ 1 -(2,3-dihydro-benzo[l .4]dioksin-5-yl)-etyl]-amid
8-butyryl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklooktylamid
• 8-[2-(2-metoksy-etoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-brom-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[3-(metyl-fenyl-amino)-propyl]-amid • 4- {[8-(2-metyl-5-nitro-benzensulfonyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(4-fluor-fenyl)-piperazin-1 -yl]-metanon • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-metyl-pyridin-3-ylmetyl-amid • 2-(3,4-dilfuor-fenyl)-l-{4-[8-(3-trifluorrnetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karbonyl]-piperazin-l-yl}-etanon • 8-(3-trilfuormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 3-{[8-(2-rnetyl-5-nitro-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-[2-(3-klor-fenoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-trifluormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-pyridin-3-ylmetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-tetrahydro-furan-2-ylmetyl)-arnid • 8-(3-trilfuormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-metyl-pyridin-3-ylmetyl-amid • 8-(pyridin-4-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzy lamid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreetyl-(2-metyl-allyl)-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(2-fluor-fenyl)-etyl]-amid • 8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(3-fenyl-akryloyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-3-ylmetyl)-amid • 8-(4-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-trifluormetylsulfanyl-berizoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(5-metyl-furan-2-ylmetyl)-amid • 8-(3-dluor-4-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(7,7-dimetyl-2-okso-bicyklo[2.2.1 ]hept-1 -ylmetansulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • 8-(2,4-difluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tetrahydro-furan-2-ylmetyl)-amid • {[8-(3-klor-tiofen-2-karbonyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karbony 1] -amino} -edikksy reety lester • 4-okso-4-{3-[(tiofen-2-ylmetyl)-karbamoyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-yl} -smørsyremetylester • 8-(2-etylsulfanyl-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 3-{[8-(2-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbony 1] -amino} -propionsyreety lester • 8-(4-trilfuormetoksy-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fenoksy-butyryl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • [8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-y 1]- [4-(4-trifluormety l-pyridin-2-yl)-piperazin-1 -yl]-metanon • 8-(2-klor-5-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-benzyloksy-cyklopentyl)-amid • 4-{[8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • 8-(2-fenoksy-propionyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [2 -(3 -metoksy-feny l)-etyl] -amid • 8-(2-metylsulfanyl-pyridin-3-karbonyl)-2-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopentylamid • 8-(4-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(naftalin-1 -ylmetyl)-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-fluor-fenyl)-etyl]-amid • 8-(4-brom-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-4-ylmetyl)-amid • 8-(4-metoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-klor-benzylamid • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-(4-o-tolyl-piperazin-1 -yl)-metanon • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-(4-pyridin-2-yl-piperazin-1 -yl)-metanon • 8-(4-trilfuormetylsulfanyl-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-fluor-benzoyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 2-(3-isobutylkarbamoyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonyl)-benzosyremetylester • 2-[(8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-3-fenyl-propionsyre-tert-butylester • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [ 1 -(2,3 -dihy dro-benzo [ 1,4]dioksin-5 -yl)-ety 1] -amid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbokslsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fiuor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(3-imidazol-1 -yl-propyl)-amid • 4-[8-(4-lfuor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperazin-1 -karboksylsyrebenzy lester • 3-(4-cykloheptyl-piperazin-1 -karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimetylamid • 4-metyl-2-{[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbony 1] -amino} -pentansyre-tert-buty lester • 8-(3-klor-2-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 2-{[8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino}-4-metyl-pentansyre-tert-butylester • 3- {[8-(6-klor-2-fluor-3-metyl-benzoyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-(2-fenoksy-propionyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(5-fluor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(2-metoksy-fenyl)-piperidin-1 -yl]-metanon • 8-(2-klor-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2-fenoksy-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopentylamid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • l-[8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyreetylester • 8-(2-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2,3-diklor-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-heksanoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopropylmetyl-amid • 8-(2,3-difluor-4-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fiuor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,5-dimetoksy-benzyl)-furan-2-ylrnetyl-amid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3 -metoksy-benzy lamid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-l-metyl-etyl]-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [2 -(3,4-diklor-fenyl)- etyl]-amid • 8-[2-(3-klor-fenoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksyslyre-(2-cyano-etyl)-(2-pyridin-2-yl-etyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-l-metyl-etyl]-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(2,6-difluor-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2-benzyloksy-acetyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(2,3-diklor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid • 8-(5-brom-2-metoksy -benzensulfonryl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopenty lamid • edikksyre-2-(3-benzylkarbamoyl-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-8-yl)-1,1 -dimetyl-2-okso-etylester • 8-[3-(2-klor-6-fluor-fenyl)-5-metyl-isoksazol-4-karbonyl]-1 -oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • [4-(3-fenyl-propyl)-piperazin-1 -yl]- [8-(4-trifluormetoksy-benzensulfony 1)-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-[3-(2-klor-6-fluor-fenyl)-5-metyl-isoksazol-4-karbonyl]-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzy lamid • 8-(naftalinkarbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • l-[8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyreetylester • 8-(3-difluormetylsulfanyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-fenyl-cyklopropyl)-amid • 8-(4-fenoksy-butyryl)-1 -oksa-2,8-diaza[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(3-klor-4-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(5-tert-butyl-2-metyl-2H-pyrazon-3-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • [8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-yl]-[4-(3-fenyl-propyl)-piperazin-1 -yl]-metanon • 8-(4-trilfuormetoksy-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-4-ylmetyl)-amid • benzosyre 2-(3-cyklopentylkarbamoyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karbonyl)-benzylester • 3-[4-(4-tert-butyl-benzyl)-piperazin-1 -karbonyl] -1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimetylamid • {[8-(2-etoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -edikksyreety lester • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(naftalin-1 -karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(3-fenyl-propyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,3-dihydro-benzo[1.4]dioksin-2-ylmetyl)-amid • l-[8-(4-tert-butyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyre-etylester • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(3-trifluormetyl-fenyl)-etyl]-amid • 8-[3-(2,6-diklor-fenyl)-5-metyl-isoksazol-4-karbonyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre- [ 1 -(naftalin-2-ylkarbamoyl)-ety l]-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 3-(4-klor-fenyl)-2- {[8-(4-metoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -propionsyre metylester • 8-(3-trilfuormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklpentyl)-amid • 8-(3-trifluormetyl-benzensulfonyl)-1 -oksa-2,8.diaza-spiro[4.5]dec-2-en-3-karboksy lsy re-(2 -fenoksy-ety 1) -amid • 8-(2-fenokys-pyridin-3-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(naftalin-2-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopropylmetyl-amid • 8-(3-klor-4-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(2-fenyl-butylryl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re-2 -fluor-benzy lamid • 8-(3-klor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • (4-benzyl-piperazin-l-yl)-[8-(2,5-diklor-benzosulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(3-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-ene-3-karboksylsyre-benzylamid • (4-benzyl-piperidin-1 -yl)-[8-(3-trifluormetyl-benzosulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzy lamid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[l-(4-nitro-fenyl)-etyl]-amid • 4-metyl-2- {[8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino]-pentansyre tert-butylester • [4-(4-fluor-feny l)-3,6-dihydro-2H-pyridin-1 -yl]-(8-fenylmetansulfonyl-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(etyl-m-toly l-amino)-etyl] -amid • 8-(2,5-dimetyl-furan-3-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • (4-cykloheptyl-piperazin-l-yl)-[8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2-benzyloksy-acetyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre benzylamid • R,R-8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklopentyl)-amid;
samt deres hydroklorider.
En ytterligere gjenstand for foreliggende oppfinnelse er en fremgangsmåte for fremstilling av l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatene med generell formel (I) ifølge oppfinnelsen som angitt i krav 13. Den fremgangsmåten er kjennetegnet ved at (a) forbindelsen med formel (II)
som er kommersielt tilgjengelig eller på enkel måte oppnåelig fra piperidin-4-on og et BOCyleringsmiddel, omsettes med et metyleneringsmiddel, fortrinnsvis Ph2PCH3Br i nærvær av kalium-tert-butylat i THF, til forbindelse (III) (b) forbindelse (III) underkastes en omsetning med etylkloroksimidoacetat (IV) i nærvær av en base, fortrinnsvis natriumhydrogenkarbonat eller litiumhydroksid, fortrinnsvis i et organisk oppløsningsmiddel, spesielt metanol, diklormetan eller THF, under dannelse av l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivater med formel (V) (c) forbindelse (V) omsettes enten direkte eller etter forutgående forsåpning av karboksylsyreetylesterfunksjonen av forbindelse (V), og eventuelt under aktivering av den derved dannede karboksylsyrefunksjonen med et amin med formel HNR<]>R<2>, hvor R og R er definert som i et av kravene 1 til 8, til l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatet med formel (VI) (d) ved fjernelse av BOC-beskyttelsesgruppen fra forbindelse (VI) oppnås forbindelse (I)medR<3>= H
og
(e) eventuelt omdannes forbindelse (I) med R3 = H med et syreklorid med formel R<I2>S02C1 til en forbindelse (I) med R<3>= S02R<12>, hvor R<12>er definert som i et hvilket som helst av kravene 1 til 8, eller med et karboksylsyreklorid med formel R<13>COCl til en forbindelse (I) med R<3>= COR<13>, hvor R<13>er definert som i et hvilket som helst av kravene 1 til 8.
Derved foregår innføringen av BOC-beskyttelsesgruppen (BOC=tert-butyloksykarbonyl) før trinn (a) samt dannelsen av ekso-metylengruppen i trinn (a) og den 1,3-dipolare cykloadderingen i trinn (b) av fremgangsmåten ifølge oppfinnelsen analogt en litteraturkjent fremgangsmåte ifølge WO 97/33887, s. 78 til 82. De avsluttende reaksjonstrinnene (c, d og evnt. e) gjennomføres - med utgangspunkt fra spiro (V) under amiddannelse ved hjelp av omsetning med et primært eller sekundært amin ((c)) (eventuelt etter forutgående spaltning av etylesteren og eventuelt under aktivering av den frie karboksylsyrefunksjonen, for eksempel med dicykloheksyl-karbodiimid (DCC), 1-hydroksybenzotriazol og trietylamin, henholdsvis N-metylmorfolin og Castro-reagens (BOP-reagens) i for eksempel DMF), fjernelse av BOC-beskyttelsesgruppen fra amid (VI) ((d)) og under eventuelt etterfølgende omsetning med syreklorider eller sulfonsyreklorider ((e)) - ved for fagmannen generelt kjente fremgangsmåter, som for eksempel angitt i "Peptide Chemistry", M. Bodansky, Springer-Verlag, 1993. Det etterfølgende reaksjonsskjemaet sammenfatter syntesen ifølge oppfinnelsen.
De i fremgangsmåten ifølge oppfinnelsen anvendte forbindelsene og reagensene er, dersom de ikke er kommersielt tilgjengelige, lett oppnåelige ved for fagmannen kjente fremgangsmåter i henhold til teknikkens stand. l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatene er toksikologisk godtagbare, slik at de egner seg som farmasøytiske virkestoffer i legemidler.
En ytterligere gjenstand for oppfinnelsen er følgelig også et legemiddel inneholdende minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat av den ovenfor definerte generelle formel (I) i form av dets racemater, rene stereoisomerer, spesielt enantiomerer eller diastereoisomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller baser eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av hydroklorider, eller i form av dets solvater, spesielt hydratene.
Legemiddelet ifølge oppfinnelsen kan administreres som flytende preparater i form av injeksjonsoppløsninger, dråper eller safter, som halvfaste preparater i form av granulater, tabletter, pellets, poser, kapsler, plastere eller aerosoler og inneholder ved siden av minst ett l-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivat med formel (I) ifølge oppfinnelsen, avhengig av galenisk form, eventuelt bærermaterialer, fyllstoffer, oppløsningsmidler, fortynningsmidler, fargestoffer og/eller bindemidler. Valget av hjelpestoffer, samt mengden som anvendes av disse, avhenger av om preparatet skal administreres oralt, peroralt, parenteralt, intravenøst, intraperetonealt, intradermalt, intramuskulært, intranasalt, bukalt, rektalt eller lokalt, for eksempel på infeksjoner i huden, slimhinnene og øynene. For oral administrering egner seg preparater i form av tabletter, dragéer, kapsler, granulater, dråper, safter og siruper, for den parenterale, topiske og inhalative tilførselen, oppløsninger, suspensjoner, lett rekonstituerbare tørrpreparater samt sprayer. l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge oppfinnelse i ett depot i oppløst form eller i et plaster, eventuelt under tilsats av midler som fremmer hudpenetreringen, er egnede perkutane administreringsformer. Oralt eller perkutant anvendbare preparatformer kan frigi de substituerte tetrahydrokinolin-derivatene ifølge oppfinnelsen med forsinkelse. Virkestoffmengden som administreres til pasienter varierer avhengig av pasientenes vekt, tilførselsmåte, indikasjonen og graden av sykdommen. Vanligvis tilføres 2 til 500 mg/kg av minst ett l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med formel (I) ifølge oppfinnelsen.
Fortrinnsvis anvendes l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatene ifølge oppfinnelsen til smertebehandling, spesielt av kroniske og nevropatiske smerter, men også ved migrene, slik at en ytterligere oppfinnelsesgjenstand, i henhold til krav 15 er anvendelsen av minst ett l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med formel (I) ifølge oppfinnelsen også i form av dets racemater; dets rene stereoisomerer, enantiomerer, diastereomerer, spesielt blandinger av enantiomerer eller diastereomerer eller en enkelt enantiomer eller diastereomer; dets baser og/eller salter med fysiologisk godtagbare syrer, spesielt hydrokloridsaltet, for fremstilling av et legemiddel for behandling av smerte, spesielt nevropatisk og/eller kronisk smerte, og/eller for behandling og/eller forebyggelse av migrene.
Overraskende har det vist seg at l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatene med generell formel (I) ifølge oppfinnelsen også er meget egnede for ytterligere indikasjoner, spesielt for behandling av urininkontinens, kløe, tinnitus aurium og/eller diaré. En ytterligere gjenstand for oppfinnelsen er følgelig anvendelsen, i henhold til krav 16, av minst ett l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med formel (I) ifølge oppfinnelsen, også i form av dets racemater, enantiomerer, diastereomerer, spesielt blandinger av dets enantiomerer eller diastereomerer eller en enkelt enantiomer eller diastereomer; dets baser og/eller dets salter med fysiologisk godtagbare syrer, spesielt hydrokloridsaltet, for fremstilling av et legemiddel for behandling og/eller profylakse av urininkontinens og/eller kløe og/eller tinnitus aurium og/eller diaré.
Fra affiniteten til BTX-bindingssetet åpner det seg ytterligere terapeutiske anvendelsesmuligheter, slik at de substituerte l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatene med generell formel (I) ifølge oppfinnelsen i form av deres racemater, deres rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller en form av blandinger av stereoisomerene spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av deres syrer eller deres baser eller i form av deres salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av deres hydroklorider, eller i form av deres solvater, spesielt hydratene; finner anvendelse for fremstilling av et legemiddel for anestesi, spesielt lokal anestesi, og/eller behandling og/eller profylakse av arytmier og /eller emesis og/eller kardiovaskulære lidelser og/eller cerebrale iskemier og/eller alkoholavhengighet og/eller drogeavhengighet og/eller medikamentavhengighet og/eller betennelser og/eller vertigo og/eller som nootropikum (neurotropikum) og/eller som muskelrelakserende middel.
Videre oppstår fra affiniteten til NMDA-reseptoren ytterligere anvendelsesområder, idet NMDA-antagonister på kjent måte blant annet har en neurobeskyttende virkning og følgelig også godt kan anvendes ved sykdomsbilder som begynner med neurodegenerering og -beskadigelse, som Morbus Parkinson og Morbus Huntington osv. Ytterligere indikasjoner for NMDA-antagonisten ifølge oppfinnelsen er epilepsi, glaukom, osteoporose, ototoksisitet, de med alkohol- og/eller drogemisbruk innledende opptredende abstinenssymptomene, slaganfall, samt dermed sammenhengende cerebrale iskemier, cerebrale infarkter, hjerneødem, hypoksi, anoksi, samt også anvendelse for anksiolyse og innenfor anestesi. Det substituerte l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatet med formel (I) ifølge oppfinnelsen, kan også anvendes i form av dets racemater; enantiomerer, diastereomerer, spesielt blandinger av dets enantiomerer eller diastereomerer eller en enkelt enantiomer eller diastereomer; dets baser og/eller salter med fysiologisk godtagbare syrer, spesielt hydrokloridsaltet, for fremstilling av et legemiddel for behandling/profylakse av epilepsi, Morbus Parkinson, Morbus Huntington, glaukom, ototoksisitet, abstinenssymptomer ved alkohol- og/eller drogemisbruk, slaganfall, cerabrale iskemier, cerebrale infarkter, hjerneødem, hypoksi, anoksi og/eller for anksiolyse og/eller anestesi.
Forbindelser med formel (I) ifølge oppfinnelsen bindes dessuten også virksomt til ct2A-reseptoren, henholdsvis har vist seg som NA-opptaks/5HT-opptakshemmer. Dermed er en ytterligere gjenstand for oppfinnelsen anvendelsen av et substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivater med generell formel (I) i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser eller i form av dets salter, spesielt fysiologisk godtagbare salter, helt spesielt foretrukket i form av dets hydroklorid, eller i form av dets solvater, spesielt hydrater, for fremstilling av et legemiddel for behandling og/eller profylakse av inflammatoriske og/eller allergiske reaksjoner og/eller gastritt og/eller ulcer og/eller depresjoner og/eller sjokktilstander og/eller narkolepsi og/eller epilepsi og/eller fedme og/eller astma og/eller glaukom og/eller hyperkenetisk syndrom i henhold til krav 18; og av energiløshet og/eller bulimi og/eller anoreksi og/eller katalepsi og/eller for anksiolyse og/eller for vigilans- og/eller libidoøkning i henhold til krav 19.
En ytterligere gjenstand for oppfinnelsen er anvendelse av et substituert l-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivat med generell formel (I) ifølge oppfinnelsen i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereoisomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller baser, eller i form av dets salter, spesielt de fysiologisk godtakbare saltene, helst spesielt foretrukket i form av det hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling og/eller profylakse av bipolare lidelser og/eller postmenopausale hetebølger og/eller amyotrofisk lateralsklerose (ALS) og/eller reflekssympatetisk dystrofi (RSD) og/eller spastisk lammelse og/eller "restless leg" syndrom og/eller ervervet nystagmus og/eller multippel sklerose og/eller Morbus Parkinson og/eller Morbus Alzheimer og/eller Morbus Huntington.
I det følgende belyses hendelsen nærmere ved hjelp av eksempler.
EKSEMPLER
De anvendte kjemikaliene og oppløsningsmidlene ble oppnådd kommersielt fra en av følgende fabrikanter: Acros, Geel; Avocado, Port of Heysham; Aldrich, Deisenhofen; Fluka, Seelze; Lancaster, Mulheim; Maybridge, Tintagel; Merck, Darmstadt; Sigma, Deisenhofen; TCI, Japan; eller fremstilt ved fremgangsmåter som er generelt kjente innen teknikkens stand.
De tynnskiktskromatografiske undersøkelsene ble gjennomført med HPTLC-ferdigplater, kieselgel 60 F 254, fra firma E. Merck, Darmstadt.
Hver prøve ble analysert med ESI-MS og/eller NMR. Massespektrometriske undersøkelser (ESI-MS) ble gjennomført med et massespektrometer fra firma Finnegan, LCQ Classic. 'H-NMR-undersøkelser av forbindelser ifølge oppfinnelsen ble gjennomført med e 300 MHZ DPX Advance NMR-apparat fra firma Bruker.
Fremstilling av substituerte l-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater ifølge oppfinnelsen
4-metylen-piperidin-l-karboksylsyre tert-butylester
Til en suspensjon av 5.34 g (15 mmol) metyltrifenylfosfoniumbromid i 50 ml dietyleter ble det under omrøring ved 0°C (isbad) tilsatt 1,6 g (14 mmol) kalium tert-butylat. Etter 15 minutters omrøring ble det langsomt tilsatt en oppløsning av 2,00 g (10 mmol) 1- boc-4-piperidin (fra Merck KgaA) i 15 ml dietyleter. Suspensjonen fikk omrøres i ytterligere 30 minutter ved 0°C. Etter tilsats av 60 ml 10% vandig Nl^Cl-oppløsning ble den organiske fasen fraskilt, tørket over magnesiumsulfat og i vakuum befridd for oppløsningsmiddel. Etter kromatografi på kieselgel (heksan:edikkester=5:l) fikk man 1.71 g (89%) 4-metylen-piperidin-l-karboksylsyretert-butylester som fargeløs væske.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.49 ppm (s, 9H, C(CH3)3); 2.16-2.19 ppm (m, 4H, CH2); 3.40-3.44 ppm (m, 4H, CH2); 4.74 (s, 2H, C=CH2).
l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester 3-etylester
Til en blanding av 0.50 g (2,6 mmol) 4-metylen-piperidin-l-karboksylsyretert-butylester og 0.60 g (3,9 mmol) 2-klor-2-hydroksyiminoedikksyreetylester i 10 ml diklormetan ble det ved 0°C (isbad) langsomt tilsatt 0.55 ml (3.9 mmol) av tidligere nydestillert trietylamin. Etter 12 timers omrøring ved RT ble det tilsatt 0.79 g (5,1 mmol) 2-klor-2-hydroksyiminoedikksyreetylester og 0.72 ml (5,1 mmol) trietylamin ved 0°C, og det ble på nytt omrørt i 24 timer. Etter vasking med 10% vandig sitronsyre og mettet vandig NaCl fikk man, etter tørking av den organiske fasen (MgSCv) og fjernelse av oppløsningsmiddelet i vakuum, en gul olje. Etter søylekromatografi på kieselgel (heksan:dietyleter = 4:1) fikk man 320 mg (39%) av l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester 3-etylester i form av en lett gul farget olje.
'H-NMR-spektrum (d6-DMSO/TMSext): 8 = 1.37 ppm (t, J=6.0 Hz, 3H, CH3), 1.46 ppm (s, 9H, C(CH3)3; 1.67-1.75 ppm (m, 2H, CH2); 1.85-.92 ppm (m, 2H, CH2); 2.96 ppm (s, 2H, CH2); 3.39-3.49 ppm (m, 2H, CH2); 3.60-3.70 ppm (m, 2H, CH2); 4.35 (q, J=6.0 Hz, 2H, CH2).
l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester
En blanding av 320 mg (1 mmol) 4-metylen-piperidin-l-karboksylsyre-tert-butylester-3-etylester i 2 ml MeOH og 70 mg (1.5 mmol) på litiumhydroksidmonohydrat i 1,3 ml H20 ble hensatt i 1,5 timer ved RT. Etter fjernelse av oppløsningsmiddelblandingen i vakuum ble resten opptatt i vann og isedikk, og fordelt, hvorved den vandige fasen ble innstilt på pH = 4 med sitronsyre. Den organiske fasen ble tørket (MgS04), og i vakuum befridd for oppløsningsmiddel. Man fikk 280 mg (98%) av den frie syren i form av et fargeløst faststoff.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.47 ppm (s, 9H, C(CH3)3; 1.73-1.78 ppm (m, 2H, CH2); 1.88-1.93 ppm (m, 2H, CH2); 2.97 ppm (s, 2H, CH2); 3.39-3.48 ppm (m, 2H, CH2), 3.65-3.74 ppm (m, 2H, CH2); 9.35 (s, 1H, COOH).
Generell fremgangsmåte for omsetning av l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3,8-dikarboksylsyre-8-tert-butylester med primære eller sekundære aminer
En blanding av en ekvivalent av l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester, 1 ekvivalent av det aktuelle aminet, 2,7 ekvivalenter av N-metylmorfolin og 1,8 ekvivalenter av Castro-reagens (BOP-reagens) i DMF ble omrørt i 12 timer ved RT. Etter fjernelse av DMF i vakuum ble resten blandet med H20 og edikkester, og fordelt. Den organiske fasen ble vasket med H20, 10% sitronsyre, mettet Na2C03-oppløsning og mettet NaCl-oppløsning, tørket (MgSC^) og i vakuum befridd for oppløsningsmiddel. Etter søylekromatografi (kieselgel, dietyletenheksan = 10:1) fikk man de aktuelle koblingsproduktene.
I noen tilfeller ble koblingen gjennomført med DCC (1 ekvivalent), 1-hydroksybenzotriazol (1 ekvivalent) og trietylamin (1 ekvivalent) i DMF ved 0°C. Etter 1 time ved 0°C lot man det oppvarmes til RT, og omrøre i ytterligere 12 timer. Deretter ble det frafiltrert og filtratet ble fordelt mellom vandig, mettet NaHC03-oppløsning og dietyleter. Den organiske fasen ble vasket med 10% sitronsyre, mettet NaHC03-oppløsning og mettet NaCl-oppløsning, tørket (MgSC^) og i vakuum befridd for oppløsningsmiddel. Etter søylekromatografi (kieselgel, dietyleter:heksan =10:1) fikk man de aktuelle koblingsproduktene.
3-benzylkarbamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester
Analogt den ovenfor angitte fremgangsmåten (med Castro-reagens) fikk man 250 mg (56%) av 3-benzylkarbamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester i form av et fargeløst faststoff fra 340 mg (1,2 mmol) l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester og 130 mg (1,2 mmol) benzylamin.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.46 ppm (s, 9H, C(CH3)3); 1.63-1.70 ppm (m, 2H, CH2); 1.79-1.89 ppm (m, 2H, CH2); 2.98 ppm (s, 2H, CH2; 3.35-3.45 ppm (m, 2H, CH2); 3.55-3.65 ppm (m, 2H, CH2); 4.51 ppm (d, J=6 Hz, 2H, N-CH2); 7.15-7.20 ppm (m, 1H, NH); 7.26-7.33 ppm (m, 5H, aryl-H).
R,R-3-(2-benzyloksy-cyklopentylkarbamoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester
Analogt den ovenfor angitte generelle fremgangsmåten (med DCC) fikk man 700 mg (55%) av R, R-3-(2-benzyloksy-cyklopentylkarbamoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester i form av et fargeløst faststoff fra 800 mg (2,8 mmol) i l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3,8-dikarboksylsyre 8-tert-butylester og 540 mg (2,8 mmol) R, R-2-benzyloksycyklopentylamin.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.46 ppm (s, 9H, C(CH3)3; 1.60-2.00 ppm (m, 9H, CH2); 2.15-2.30 ppm (m, 1H, CH2); 2.99 ppm (s, 2H, CH2); 3.40-3.50 ppm (m, 2H, CH2); 3.59-3.65 ppm (m, 2H, CH2); 3.80-3.90 ppm (m, 1H, CH); 4.25-4.35 ppm (m, 1H, CH); 4.61 ppm (m, 2H, 0-CH2); 6.51-6.53 ppm (m, 1H, NH); 7.25-7.34 ppm (m, 5H, aryl-H).
Generell fremgangsmåte for avspaltning av Boc-gruppen
Det tilsvarende N-boc-piperidinet ble blandet med et overskudd av en 4M metanolisk HCl-oppløsning ved RT og ble omrørt (DC-kontroll). Etter fullstendig reaksjon ble oppløsningen inndampet inntil første uklarhet, deretter blandet med dietyleter og for fullstendiggjørelse av utfellingen lagret ved 4°C over natten. Det utfelte stoffet ble frafiltrert, vasket med små porsjoner dietyleter og tørket i vakuum.
l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre benzylamid-hydroklorid
Analogt den tidligere beskrevne fremgangsmåten ble det fra 250 mg (0.7 mmol) 3-benzylkarbamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester oppnådd 130 mg (60%) l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre benzylamid som hydroklorid i form av et fargeløst faststoff.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.92-2.06 ppm (m, 4H, CH2); 3.10-3.18 ppm (m, 6H, CH2); 4.31-4.40 ppm (m, 2H, CH2); 7.15-7.33 ppm (m, 5H, aryl-H); 8.99-9.13 ppm (m, 3H, NH).
R, R-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklop entyl)-amid-hydroklorid
Analogt den generelle fremgangsmåten ble det fra 700 mg (2,5 mmol) R, R-3-(2-benzyloksy-cyklopentylkarbamoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karboksylsyre-tert-butylester oppnådd 490 mg (50%) R, R-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklopentyl)-amid som hydroklorid i form av et fargeløst faststoff.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.50-1.75 ppm (m, 4H, CH2); 1.92-2.11 ppm (m, 6H, CH2); 3.06-3.20 ppm (m, 6H, CH2); 3.82-3.95 ppm (m, 1H, CH); 4.10-4.20 ppm (m, 1H, CH); 4.42-4.60 ppm (m, 2H, 0-CH2); 7.20-7.34 ppm (m, 5H, aryl-H); 8.47-8.54 ppm (m, 1H, NH); 9.05-9.15 ppm (m, 2H, NH).
Generell fremgangsmåte for omsetning av piperidinene med karboksylsyrehalogenider eller sulfonsyrehalogenider
Til en oppløsning av det tilsvarende syrehalogenidet (1.5 ekvivalenter), trietylamin (2 ekvivalenter) og N,N-dimetyl-4-aminopyridin (DMAP; katalytiske mengder) i diklormetan ble ved 0°C det aktuelle piperidinet (1 ekvivalent) tilsatt. Man lot dette oppvarmes til RT og omrøres over natten. Etter hydrolyse med 10% vandig NH4CI-oppløsning ble den organiske fasen tørket (MgS04), og i vakuum befridd for oppløsningsmiddel. Etter søylekromatografi på kieselgel (edikkester-heksan-blandinger av variabel sammensetning) fikk man den ønskede forbindelsen.
8-(2-benzyloksy-acetyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre benzylamid (eksempel 219)
Analogt den ovenfor angitte generelle fremgangsmåten ble 120 mg (0.42 mmol) 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyrebenzylamid (base, satt fri med vandig NaOH) omsatt med 116 mg (0.63 mmol) benzyloksyacetylklorid til 60 mg (34%) 8-(2-benzyloksy-acetyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzy lamid. Man fikk en fargeløs olje som ved lengre henstand ved romtemperatur langsomt krystalliserte.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 = 1.55-1.69 ppm (m, 2H, CH2); 1.75-1.85 ppm (m, 2H, CH2); 2.92 ppm (s, 2H, CH2); 3.20-3.32 ppm (m, 1H, CH2); 3.35-3.48 ppm (m, 1H, CH2); 3.50-3.60 (m, 1H, CH2); 3.94-4.05 ppm (m, 1H, CH2); 6.95-7.05 ppm (m, 1H, NH); 7.15-7.35 ppm (m, 10H, aryl-H).
R,R-8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklopentyl)-amid (eksempel 220)
Som beskrevet ovenfor ble 490 mg (1.24 mmol) av R,R-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklopentyl)-amid (base, satt fri med vandig NaOH) omsatt med 410 mg (1.86 mmol) 5-klortiofen-2-sulfonylklorid til 480 mg (72%) 8-(5-klor-tiofen-2-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre (2-benzyloksy-cyklopentyl)-amid. Man fikk et fargeløst, krystallinsk faststoff.
'H-NMR-spektrum (d6-DMSO/TMSext.): 8 =1.40-1.55 ppm (m, 1H, CH2); 1.60-2.05 ppm (m, 8H, CH2); 1.20-2.30 ppm (m, 1H, CH2); 2.93-3.05 ppm (m, 2H, CH2); 2.00 ppm (m, 2H, CH2); 3.41-3.55 ppm (m, 2H, CH2); 3.75-3.88 ppm (m, 1H, CH); 4.20-4.32 ppm (m, 1H, CH); 4.42-4.60 ppm (m, 2H, 0-CH2); 6.42-6.48 (d, 1H, aryl-H); 7.00 ppm (d, J=3 Hz, 1H, aryl-H); 7.22-7.40 ppm (m, 5H, aryl-H).
Ved denne fremgangsmåten fremstilles de i tabell 1 oppførte forbindelsene; alternativt er fremstillingen også mulig parallellsyntetisk på halv automatisert måte.
Farmakologisk testing
Substituerte l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivater ifølge oppfinnelsen ble
5underkastet følgende farmakologiske tester:
Bindingsundersøkelser på natriumkanal
Bindingssete 2 (BTX-binding):
10Bindingssete 2 av natriumkanalen er det såkalte Batrachotoksin (BTX) bindingssetet. Som ligand ble det anvendt [<3>H]-Barachotoksinin A20 a-benzoat (10 nM i blanding) i blandingen. Disse ionekanalpartiklene (synaptosomene) ble anriket fra rotte-cerebrokorteks ifølge Gray og Whittaker (E.G. Gray og V.P. Whittaker (1962) J. Anat. 76. 79-88). Som uspesifikk binding er den radioaktiviteten definert som måles i nærvær is av Veratridin. Inkubering ved 37°C i 120 minutter. Analysebetingelsene er gjennomført
i henhold til publikasjonen til Pauwels, Leysen og Laduron (P. J. Pauwels, J.E. Leysen og P.M. Laduron (1986) Eur. J. Pharmacol. 124, 291-298).
Forbindelser ifølge oppfinnelsen ble testet i denne analysen; hvor resultatene er gjengitt20i tabell 2:
Undersøkelser vedrørende Noradrenalin-gjenopptakshemning (NA-opptakshemning)
5For å kunne gjennomføre disse in vitro-undersøkelsene isoleres synaptosomer friskt fra rottehjernearealet. Hver gang kjenner en såkalt "P2"-fraksjon anvendelse, som prepareres i henhold til beskrivelsen til Gray og Whittaker (E.G. Gray og V.P. Whittaker (1962) J. Anat. 76,79-88). For NA-opptaket isoleres disse vesikulære
partiklene fra hypotalmus av mannlige rottehjerner.
10
Følgende karakteristiske data ble bestemt fra NA-transporteren:
NA-opptak: Km = 0.32 ± 0.11 uM
is (I hvert tilfelle N = 4, det vil si middelverdier ± SEM fra 4 uavhengige forsøksrekker som ble gjennomført i tre ganger-parallellforsøk).
En detaljert metodebeskrivelse finnes i litteraturen (M.Ch. Frink, H.-H. Hennies, W.
Englberger, M. Haurand og B. Wilffert (1996) Arzneim. -Forsch./Drug Res. 46 (III),2011, 1029-1036).
Forbindelser ifølge oppfinnelsen ble testet i denne analysen; måleresultatene er gjengitt i tabell 3:
Undersøkelser vedrørende serotonin-gjenopptakshemning (5HT-opptakshemning)
For å kunne gjennomføre disse in vitro-undersøkelsene isoleres synaptosomer friskt fra rottehjernearealer. I hvert tilfelle anvendes en såkalt "P2"-fraksjon, som ble preparert i henhold til fremgangsmåten til Gray og Whittaker (E.G. Gray og V.P.Whittaker (1962) J. Anat. 76, 79-88). For 5HT-opptaket isoleres disse vesikulære partiklene fra hypothalamus av mannlige rottehjerner.
En detaljert metodebeskrivelse finnes i litteraturen (M.Ch. Frink, H.-H. Hennies, W. Engleberger, M. Haurand og B. Wilffert (1996) Arzneim.-Forsch./Drug Res. 46 (III), 11, 1029-1036).
Forbindelser ifølge oppfinnelsen ble testet i denne analysen; hvor resultatene er gjengitt i tabell 4:
ci2A-analyse
Her måles bindingen over fortregningen av en merket ligand. Testen ble gjennomført i henhold til en beskrivelse av J.P. Devlin, "High throughput screening - the discovery of bioactive substances", s. 275-453, Marcel Dekker, New York, 1997. Membraner som inneholder a-reseptorer av undertypen (human) ble oppnådd kommersielt.
Forbindelser ifølge oppfinnelsen ble testet i denne analysen; måleresultatene er gjengitt i tabell 5:
Reseptorbinding (glycin-bindingssetet av NMDA-reseptorkanalen)
Undersøkelsene for bestemmelse av affiniteten av forbindelsene ifølge oppfinnelsen til glycin-bindingssetet av NMDA-reseptorkanalen ble gjennomført på hjernemembran-homogenatet (homogenater av Cortex- og Hippocampus-areal fra hjernen av hannrotter, Wistarstamme) [B.M. Baron, B.W. Siegel, B.L. Harrison, R.S. Gross, C. Hawes og P. Towers, Journal og Pharmacology and Experimental Therapeutics, vol. 279, s. 62, 1996].
For dette formålet ble Cortex og Hippocampus fripreparert fra friskt uttatte rottehjerner, og homogenisert i 5 mmol/1 TRIS-acetatbuffer, 0.32 mol/l sakkarose pH 7.4 (10 ml/g friskvekt) med en Potter-homogenisator (Firma Braun/Melsungen 10 kolbeløft ved 500 opm) under isavkjøling, og deretter sentrifugert i 10 minutter ved 1000 g og 4°C. Den første supernatanten ble samlet og sedimentet ble på nytt homogenisert med 5 mmol/TRIS-acetatbuffer, 0.32 mol/l sakkarose pH 7.4 (5 ml/g opprinnelig friskvekt) med Potter-homogenisatoren (10 kolbeløft ved 500 opm) under isavkjøling, og sentrifugert i 10 minutter ved 1000 g og 4°C. Den resulterende supernatanten ble forenet med supernatanten fra den første sentrifugeringen og sentrifugert ved 17 000 g i 20 minutter ved 4°C. Supernatanten etter denne sentrifugeringen blir kastet, og membransedimentet ble opptatt med 5 mmol/1 TPJS-acetatbuffer pH 8.0 (20 ml/g opprinnelig friskvekt) og homogenisert med 10 kolbeløft ved 500 opm.
Deretter ble membranhomogenatet inkubert i 1 time ved 4°C, og sentrifugert i 30 minutter ved 50 000 g og 4°C. Supernatanten ble kastet, og sentrifugerar med membransedimentet, ble lukket med parafilm og frosset ned i 24 timer ved -20°C. Den påfølgende dagen ble membransedimentet opptint, og opptatt med iskald 5 mmol/1 TPJS-acetatbuffer, 0.1% saponin (vekt/volum) pH 7.0 (10 ml/g opprinnelig friskvekt), homogenisert med 10 kolbeløft ved 500 opm og deretter sentrifugert i 20 minutter i 50 000 g og 4°C. Den resulterende supernatanten ble kastet, og sedimentet ble opptatt i små volumer med 5 mmol/1 TIRS-acetatbuffer pH 7.0 (ca 2 ml/g opprinnelig friskvekt), og på nytt homogenisert med kolbeløft ved 500 opm. Etter bestemmelse av proteininnholdet ble membranhomogenatet innstilt med 5 ml/l TPJS-acetatbuffer pH 7.0 på en proteinkonsentrasjon på 10 mg protein/ml og frosset inn i porsjoner inntil testing.
For reseptorbindingstesten ble porsjoner opptint, fortynnet 1:10 med 5 ml/l TRIS-acetatbuffer pH 7.0, homogenisert med 10 kolbeløft ved 500 opm med Potter-homogenisatoren (10 kolbeløft ved 500 opm) under isavkjøling, og sentrifugert i 60 minutter ved 55 000 g ved 4°C. Supernatanten ble dekantert, og membransedimentet ble, med iskald 50 mmol/1 TPJS-acetatbuffer pH 7.0, innstilt på en proteinkonsentrasjon på 1 mg/ml og på nytt homogenisert med 10 kolbeløft ved 500 opm, og under omrøring på en magnetrører holdt i suspensjon i isbad. Dette membranhomogenatet ble anvendt i reseptorbindingstesten. 1 bindingstesten ble det som buffer anvendt 50 mmol/1 TRIS-acetatbuffer pH 7.0, samt som radioaktiv ligand 1 nmol/1 (<3>H)-MDL 105.519 (B.M. Baron et al. 1996). Andelen av uspesifikk binding ble bestemt i nærvær av 1 mmol/1 Glycin.
I ytterligere blandinger ble forbindelsene ifølge oppfinnelsen tilsatt i konsentrasjonsrekker, og fortregningen av den radioaktive liganden fra dens spesifikke binding til glycin-bindingssetet av NMDA-reseptorkanalen ble bestemt. Blandingene ble inkubert i 120 min ved 4°C, og deretter for bestemmelse av den til membran homogenatetbundende liganden høstet ved hjelp av filtrering gjennom glassfiber-filtermatter (GF/B). Den på glassfiberfilterne tilbakeholdte radioaktiviteten ble målt etter tilsats av scintillator i (}-teller.
Forbindelse ifølge oppfinnelsen ble testet i denne analysen; måleresultatene er gjengitt i tabell 6:
Farmasøytisk formulering av et legemiddel ifølge oppfinnelsen
1 gram av hydrokloridet av 8-(2,5-diklorbenzosulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre[l-(3-metoksybenzyl)-pyrrolidin-3-yl]amid (eksempel 64) ble oppløst i 1 1 vann for injeksjonsformål ved romtemperatur, og deretter ved tilsats av natriumklorid innstilt på isotoniske betingelser.
Claims (20)
1.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat,karakterisert vedgenerell formel (I)
i form av dens racemater, deres rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av deres syrer eller deres baser eller i form av deres salter eller solvater;
hvori
R1 og R2 uavhengig av hverandre betyr H, Ci-Cig-alkyl, C3-Cio-cykloalkyl, (C1-12-
alkyl)-C3-io-cykloalkyl, aryl (Ci-i2-alkyl)-aryl, heterocyklyl eller NH-C(=0)-aryl, hvorved minst en av restene R<1>og R2 ikke betyr H,
eller
står sammen for-(CR<4>R<5>)m-(CR<6>R<7>)n-Y-(CR<8>R9)p-(CR<I0>R<n>)q- med m, n, p og q i hvert tilfelle = 0, 1, 2, 3, 4 eller 5, under den forutsetningen at m+n > 1 og p+q > 1, eller står for -CH2-CH2-C(-aryl)=CH-CH2-;
R<3>betyr H, S02R<12>eller COR<13>;
R<4>, R<5>, R<6>,
R<7>, R<8>, R<9>,
R1<0>og R<11>står uavhengig av hverandre for H, Q-io-alkyl, C3-8-cykloalkyl, (C1-6-
alkyl)-C3.g-cykloalkyl, aryl, (C].6-alkyl)-aryl, heterocykyl, (Ci-6-alkyl)-heterocyklyl eller betyr C(=0)R<14>;
Y betyr CR<I5>R<16>, NR<17>eller O;
R<1>2ogR1<3>betyr uavhengig av hverandre Ci-io-alkyl, C3.10-cykloalk.yl, (Ci.6-alkyl)-
C3-io-cykloalkyl, aryl, (Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller NRI8R19;
R<14>betyr H, Ci-io-alkyl, C3-8-cykloalkyl, (Ci.6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci.6-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller OR<20>;
R1<5>og R<16>betyr uavhengig av hverandre H, Ci-10-alkyl, C3-g-cykloalkyl, (C1-6-
alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl, (Ci^-alkyl)-heterocyklyl eller C(=0)R<21>;
R<17>betyr H, Ci-io-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci.6-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller C(=0)R<22>;
R<1>8 ogR1<9>betyr uavhengig av hverandre H, Ci-10-alkyl, C3_8-cykloalkyl, (C1-6-
alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl eller (C1-6-alkyl)-heterocyklyl;
R<20>betyr H, Ci-io-alkyl, C3.8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci-6-alkyl)-aryl, heterocyklyl eller (Ci^-alkyl)-heterocyklyl;
R<21>betyr H, Ci-10-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl, (Ci.6-alkyl)-heterocyklyl eller OR<23>;
R<22>betyr H, Ci-10-alkyl, C3-8-cykloalkyl, (Ci-6-alkyl)-C3-8-cykloalkyl, aryl,
(Ci^-alkyl)-aryl, heterocyklyl, (Ci-6-alkyl)-heterocyklyl eller OR24og
R<2>3ogR2<4>betyr uavhengig av hverandre H, Q-io-alkyl, C3-8-cykloalkyl, (C1-6-
alkyl)-C3-8-cykloalkyl, aryl, (Ci-6-alkyl)-aryl, heterocyklyl eller (C1-6-alkyl)-heterocyklyl;
hvori aryl betyr en rest valgt fra gruppen bestående av fenyl, naftyl, fenantrenyl, antracenyl, og bifenyl, eventuelt substituert med Ci^-alkyl, F, Cl, Br, I, CF3, O-C1-6-alkyl, OCF3, fenyl, CN og N02; og
heterocyclyl betyr en rest valgt fra gruppen bestående av pyrrolidinyl, tetrahydrofuryl, 1,4-dioksanyl, piperidinyl, piperazinyl og morfolinyl, eventuelt substituert med Ci^-alkyl, F, Cl, Br, I, CF3, O-Ci-e-alkyl, OCF3, fenyl, CN og N02,
hvor alkyl eventuelt er substituert med F, Cl, Br, CN, NH2, NH-alkyl, NH-aryl, NH-alkyl-aryl, NH-heterocyklyl, N(alkyl)2, N(alkyl-aryl)2, N-alkyl-N-aryl, N02, OH, O-alkyl, S-alkyl, O-aryl, O-alkyl-aryl, O-alkyl-O-alkyl, C(=0)-Ci.6-alkyl, C(=0)-aryl, C(=0)-Ci-6-alkyl-aryl, C(=0)-heterocyklyl, C02H, C02-alkyl-aryl, C(=0)NH2, C(=0)NH-alkyl, C(=0)NH-aryl, C(=0)NH-heterocyklyl, C(=0)N(alkyl)2, C(=0)N(alkyl-aryl)2, cykloalkyl, aryl eller heterocyklyl,
hvori
alkyl er valgt fra gruppen bestående av metyl, etyl, n-propyl, n-butyl, iso-butyl, sek-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-heksyl, 2-heksyl, n-heptyl, n-oktyl, n-nonyl, n-decyl, n-dodecyl, etenyl (vinyl), etinyl, propenyl, (-CH2CH=CH2,-CH=CH-CH3,-C(=CH2)-CH3), propinyl (-CH2-CeCH,-CeC-CH3) og butenyl;
cykloalkyl er valgt fra cyklopropyl, cyklobutyl, cyklopentyl, cyckloheksyl, cykloheptanyl, cyklooktanyl, adamantanyl og bicyklo[3.1.1]heptan-3-yl;
aryl er valgt fra gruppen bestående av fenyl, naftyl, fenantrenyl, antracenyl og bifenyl; og
heterocyklyl er valgt fra gruppen bestående av pyrrolidinyl, tetrahydrofuryl, 1,4-dioksanyl, piperidinyl, piperazinyl, morfolinyl, pyrrolyl, furanyl, tienyl, pyrazolyl, imidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoksazolyl, tieno[2,3-d]pyrimidinyl, indolyl og pyridinyl.
2.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 1,karakterisert vedat
R1 og R2 uavhengig av hverandre betyr H, Ci-g-alkyl, C3-g-cykloalkyl, (Ci.
4-alkyl)-C3-8-cykloalkyl, aryl, (Ci-4-alkyl)-aryl, heterocyklyl, (Ci.4-alkyl)-heterocyklyl eller NH-C-(=0)-aryl, hvorved minst en av restene R<1>og R2 ikke betyr H,
eller
står sammen for -(CR<4>R<5>)m-(CR<6>R<7>)n-Y-(CR<8>R<9>)p-(CR<10>R11)q-med m=l, n=0 eller 1, p=l eller 2 og q=l eller 2, eller står for - CH2-CH2-C(-aryl)=CH-CH2-;
R<3>betyr S02R<12>eller COR<13>;
R<4><lj5><p>6p7<p8>
, IV , IV , IV , IV ,
R9,R1<0>og R<11>betyr uavhengig av hverandre H, Ci-g-alkyl eller C(=0)R<14>;
Y betyr CR<I5>R<16>eller NR<17>;
R12betyr C^-alkyl, (Ci-4-alkyl)-C3-8-cykloalkyl, aryl, (C^-alkyl)-
aryl, heterocyklyl eller NR<I8>R<19>;
R<13>Ci-6-alkyl, C3-io-cykloalkyl, aryl, (Ci-4-alkyl)-aryl eller heterocyklyl; R<14>betyr OR<20>;
R<15>og R<16>betyr uavhengig av hverandre H, aryl eller (Ci-4-alkyl)-aryl;
R<17>betyr H, C3-8-cykloalkyl, aryl, (Ci-4-alkyl)-aryl, heterocyklyl eller
C(=0)R<22>;
R<18>og R<19>betyr uavhengig av hverandre H eller Ci-6-alkyl;
R<20>betyr Ci.6-alkyl;
R<22>betyr aryl, (Ci^-alkyl)-aryl, heterocyklyl eller OR24;og R<24>Ci-e-alkyl eller (Ci-4-alkyl)-aryl.
3.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 1 eller 2,karakterisert vedat
R<1>betyr Ci-e-alkyl, C3.8-cykloalkyl, (Ci-3-alkyl)-C3-8-cykloalkyl,
aryl, (Ci-3-alkyl)-aryl, heterocyklyl, (Ci-3-alkyl)-heterocyklyl eller NH-C(=0)-aryl; og
R<2>betyr H, C^-alkyl, (Ci-3-alkyl)-aryl eller (Ci.3-alkyl)-
heterocyklyl.
4.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 3,karakterisert vedat
R<1>betyr usubstituert eller med F, Cl, Br, I, -CN, N-Ci-6-alkyl-N-
arylamin, N,N-dialkylamin, amid, karboksylalkyl, karboksybenzyl, substituert metyl, etyl, n-propyl, iso-propyl, 2-metylpropyl, n-butyl, tert-butyl, n-pentyl, 3-metylbutyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl, CH2-C(CH3)=CH2, CH(C(=0)OCH2CH=CH2)-CH2CeO)0-tert-but<y>l, 2-cyanoetyl, CH2-CH2-NH-C(=0)CH3, 2-(N-etyl-N-(3-metylfenyl)amino)-etyl, 2-(N,N-dimetylamino)-etyl, 2-(C(=0)-NH-((5-naftyl)-etyl, 1,2-(di-(C(=0)0-tert-butyl)etyl, 3-(N-metyl-N-fenylamino)-propyl, l-(C(=0)0-benzyl)-3-metyl-butyl, l-(C(=0)0-butyl)-3-metyl-butyl, CH2C02etyl, CH2-CH2C02etyl, CH2-CH2-Ofenyl, CH2-CH2-S-CH2-CH3;
usubstituert eller med F, Cl, Br, I, -CN, Ci-6-alkyl, aryl, karboksylalkyl, karboksybenzyl, O- Ci-6- alkyl, O-benzyl substituert cyklopropyl, cyklobutyl, cyklopentyl, cykloheksyl, cykloheptyl, cyklooktyl, bicyklo[3.1.1]heptan-3-yl, spesielt 2-fenylcylopropyl, 2-(0-benzyl)-cyklopentyl, 2-(karboksyletyl)cykloheksyl, 7,7-dimetyl-2-(karboksyetyl)cykloheksyl, 7,7-dimetyl-2-metylbicyklo[3.1.1]heptan-3-yl; cyklopropylmetyl, 7,7-dimetyl-2-okso-bicyklo[2.2.1 ]hept-1 -ylmetyl;
usubstituert eller med fenoksy, -CH2-P (=0)(Oetyl)2substituert fenyl, 1-naftyl eller 2-naftyl; CH2-aryl, CH2-CH2-aryl, CH2-CH2-CH2-aryl, CH2-CH2-CH2-CH2-aryl CH(CH3)-aryl, CH(CH3)-CH2-aryl, CH2-CH-(aryl)2, CH(C02alkyl)-CH2-aryl, CH2-CH2-CH-(aryl)2, hvorved aryl er usubstituert fenyl, 1-naftyl eller 2-naftyl eller med F, Cl, Br, I, -CN, -N02, alkyl, CF3, alkoksy, alkylendioksy, substituert fenyl, spesielt benzyl, -CH2-naft-l-yl, 2- fluorbenzyl, 3-fluorbenzyl, 3-klorbenzyl, 3-metoksybenzyl, 2-etoksybenzyl, 2,4-difluorbenzyl, 3,5-diklorbenzyl, 3-fluor-5-trifluormetylbenzyl, 3-fluor-4-trifluormetylbenzyl, 2-klor-6-fluorbenzyl, 2,5-dimetoksybenzyl, 2-klor-6-metyl-benzyl, 3,4-dimetoksybenzyl, 3,4-dioksymetylenbenzyl, CH(CH3)-fenyl, CH(CH3)-(4-CH3-fenyl), CH(CH3)-(4-nitrofenyl), CH(CH3)-(2,3-dioksyetylenfenyl), CH2-CH2-fenyl, CH2-CH2-(2-lfuorfenyl), CH2-CH2-(3-fluorfenyl), CH2-CH2-(4-fluorfenyl), CH2-CH2-(4-klorfenyl), CH2-CH2-(3,4-diklorfenyl), CH2-CH2-(3-metoksyfenyl), CH2-CH2-(2,5-dimetoksyfenyl), CH(C02-tert-butyl)-CH2-fenyl, CH(C02-metyl)-CH2-(4-klorfenyl), CH2-CH(fenyl)2, CH(CH3)-CH2-(4-klorfenyl), CH2-CH2-CH(fenyl)2, CH2, CH2-CH2-fenyl;
usubstituert eller med aryl, alkylaryl eller karboksyetyl substituert pyrrolidin eller piperidin, spesielt pyrrolidin-3-yl, N-(4-trifluorbenzyl)-pyrrolidin-3-yl, N-(3-metoksybenzyl)-pyrrolidin-3- yl, N-(CH2-(p-naftyl)-pyrrolidin-3-yl eller N-(karboksyetyl)-piperidin-4-yl; usubstituert eller med alkyl, F, Cl, Br, I, -CN, aryl, alkylaryl, substituert (CH2)i_3-heterocyklyl, hvorved heterocyklyl står for furanyl, benzofuranyl, 1,4-dioksanyl, benzo-1,4-dioksanyl, tienyl, pyridinyl, pyrrolidinyl, lH-indolyl, imidazolyl, piperidinyl, tetrahydrofuranyl, spesielt, CH2-furan-2-yl, 5-metylfuran-2-yl CH2-benzofuran-2-yl,
CH2-tien-2-yl, CH2-pyridin-3-yl, CH2-pyridin-4-yl, CH2-CH2-pyridin-2-yl, CH2-CH2-(lH-indol-3-yl), CH2-CH2-pyrrolidin-l-yl, CH2-(N-2,6-diklorbenzylpyrrolidin-3-yl), CH2-CH2-(N-metyl-pyrrolidin-2-yl), -CH2)3-imidazol-l-yl, CH2-(tetrahydrofuran-2-yl) eller -H2C-H2C-H2C
, eller CH(C02metyl)-CH2-(lH-indol-3-yl); NH-C(=0)-(4-dietylaminofenyl); ogR<2>står for H;
usubstituert, eller med F, Cl, Br, I, -CN substituert metyl, etyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl eller CH2-C(CH3)=CH2, spesielt metyl, etyl, 2-cyanoetyl, CH2-C(CH3)<=>CH2;
usubstituert, eller med F, Cl, Br, I, -CN, metoksy, etoksy, substituert benzyl eller fenetyl, spesielt benzyl, 4-fluorbenzyl, 2-klor-6-fluorbenzyl, 2,5-dimetoksybenzyl, fenetyl; eller
CH2-furanyl, spesielt CH2-furan-2-yl, CH2-benzofuranyl, spesielt CH2-benzofuran-2-yl, CH2-pyridinyl, spesielt CH2-pyridin-3-yl, CH2-tetrahydrofuranyl, spesielt CH2-tetrahydrofuran-2-yl, CH2-CH2-pyridinyl, spesielt CH2-CH2-pyridin-2-yl.
5.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 1 eller 2,karakterisert vedat
R<1>og R<2>sammen står for
hvori aryl betyr fenyl eller med F, Cl, Br, I substituert fenyl, spesielt 4-fluorfenyl;
R<6>betyr H eller Ci-4-alkyl, spesielt metyl;
R<10>betyr H, C(=0)Ometyl, C(=0)Oetyl, C(=0)0-n-propyl, C(=0)0-
iso-propyl, C(=0)0-iso-propyl, C(=0)0-n-butyl, C(=0)0-tert-butyl;
R<15>betyr H eller CH2-aryl;
R<16>betyr H;
R<17>betyr H;
C3-g-cykloalkyl, spesielt cykloheptyl; aryl, spesielt usubstituert eller med metyl, etyl, n-propyl, iso-propyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, metoksy, etoksy, n-propyl, iso-propoksy, n-butoksy, tert-butoksy substituert fenyl eller naftyl; ((CH2)i-3-alkyl)-aryl eller CH(CH3)-aryl, hvorved aryl betyr usubstituert eller med alkyl, CF3, F, Cl, Br, I, -CN, alkoksy substituert fenyl eller naftyl; usubstituert eller med alkyl, CF3, F, Cl, Br, I, -CN, alkoksysubstituert pyridinyl, pyrazinyl eller tieno[2,3-d]pyrimidinyl; eller betyr C(=0)R22;og
R<22>betyr fenyl eller alkoksysubstituert fenyl, O-metyl, O-etyl, O-n-
propyl, O-iso-propyl, O-n-butyl, O-tert-butyl, O-benzyl, usubstituert benzyl med F substituert benzyl, usubstituert pyrazinyl eller med alkyl substituert pyrazinyl.
6.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 5,karakterisert vedat
R<6>betyr H eller metyl;
R<10>betyr H eller C(=0)Oetyl;
R<15>betyr H eller benzyl;
R16betyr H; og
R<17>betyr H;
cykloheptyl;
fenyl, 2-metylfenyl, 3-metylfenyl, 2,4-dimetylfenyl, 2-etylfenyl, 3-trifluormetyl, 4-fluorfenyl, 4-klorfenyl, 2-metoksyfenyl, 3,5- dimetoksyfenyl, 3-klor-6-metylfenyl, benzyl, CH2-(4-tert-butylfenyl), CH2-((5-naftyl), CH(CH3)-fenyl, (CH2)3-fenyl; pyridin-2-yl, (4-trifluormetyl)-pyridin-2-yl, tieno[2,3-d]pyrimidin-4-yl; eller
C(=0)-(4-metoksyfenyl), C(=0)-benzyl, C(=0)-CH2-(3,4-difluorfenyl), C(=0)-(2-metylpyrazin-5-yl), C(=0)0-tert-bøutyl eller O-benzyl.
7.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge hvilket som helst av krav 1 til 6,karakterisert vedat
R<3>betyr S02R<12>;
R<12>betyr metyl, etyl, n-propyl, iso-propyl, spesielt n-propyl;
7.7-dimetyl-2-okso-bicyklo[2.2.1]hept-l-ylmetyl; fenyl eller med metyl, etyl, n-propyl, isopropyl, n-butyl-tert-butyl-CF3, F, Cl, Br, I, -CN, N02, metoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, tert-butoksy, OCF3, C02metyl substituert fenyl, spesielt 4-metylfenyl, 3-trifluormetylfenyl, 4-fluorfenyl, 2-klorfenyl, 3-klorfenyl, 4-klorfenyl, 4-metoksyfenyl, 4-trifluormetoksyfenyl, 4-nitrofenyl, 2-C02metyl-fenyl, 2,5-diklorfenyl, 3-fluor-6-metylfenyl, 3-brom-6-metoksyfenyl, 2-metyl-5-nitrofenyl, 2,4,6-trimetylfenyl;
benzyl eller med metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, N02, metoksy, etoksy, n-propoksy, iso-propoksy, n-butoksy, tert-butoksy, OCF3substituert benzyl; usubstituert eller med metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, N02, metoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, tert-butoksy substituert furanyl eller tianyl, spesielt tien-2-yl, 5-klortien-2-yl eller NRI8R1<9>; og
R<18>og R<19>betyr uavhengig av hverandre H, metyl eller etyl.
8.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge hvilket som helst av krav 1 til 6,karakterisert vedat
R<3>betyr COR13;og
R<13>betyr usubstituert eller med O-mety 1, O-etyl, 0-(CH2)2-OCH3, O-
benzyl, O-fenyl, hvorved fenyl er usubstituert eller er substituert med F, Cl, Br, I, -CN, 0-C(=0)-metyl, 0-C(=0)-etyl substituert metyl, etyl, C(=0)0-metyl, n-propyl, iso-propyl, 2-metylpropyl, n-butyl, tert-butyl, n-pentyl eller 3-metylbutyl, spesielt metyl, etyl, n-propyl, n-butyl, tert-butyl, n-pentyl, CH2-0-CH2-CH2-OCH3, CH(CH3)-0-fenyl, CH2CH2-C(=0)OCH3, C(CH3)2-OC(=0)CH3, CH2-0-benzyl, CH2-0-(3-klorfenyl), CH2-CH2-CH2-0-fenyl, CH(OC(=0)metyl)CH3; cyklopropyl, 2-fenylcyklopropyl, 1-adamantyl; usubstituert eller med F, Cl, Br, I, -CN, fenyl, metyl, etyl, n-propyl, isopropyl, n-butyl, tert-butyl, CF3, F, Cl, Br, I, -CN, N02, metoksy, etoksy, n-propoksy, iso-propoksy, n-butoksy, tert-butoksy, OCF3, OCHF2, OCH2F, SCF3, SCHF2, SCH2F, SCH3, CH2OC(=0)fenyl, -N(CH3) substituert fenyl eller naftyl, spesielt 4-fluorfenyl, 2-klorfenyl, 3-klorfenyl, 4-bromfenyl, 4-fenylfenyl (4-bifenyl), 4-etylfenyl, 4-CF3-fenyl, 4-metoksyfenyl, 2-etoksyfenyl, 4-tert-butyl, 3-OCF3-fenyl, 4-OCF3-fenyl, 4-SCF3-fenyl, 3-SCF2-fenyl, 2-CH2-OC(=0)fenyl, 3-dimetylaminofenyl, 2,3-diklorfenyl, 2,4-difluorfenyl, 3-klor-4-fluorfenyl, 3-klor-2-fluorfenyl, 4-CF3-3-fluorfenyl, 3-CF3-6-fluorfenyl, 4-brom-3-metylfenyl, 2-klor-4-nitrofenyl, 2,3,4,5,6-pentafluorfenyl, 2,6-difluor-3-metylfenyl, 2,3-difluor-4-metylfenyl, 2-klor-5-metyl-6-fluorfenyl, 1-naftyl, 2-naftyl;
usubstituert eller substituert (Ci.2-alkyl)-aryl, spesielt benzyl, fenetyl, CH(C2H5)-fenyl, CH(NH-S02-(4-metylfenyl))-CH2-fenyl, CH=CH-fenyl, CH=CH-(3-trifluorfenyl); eller usubstituert eller alkyl substituert furanyl, benzofuranyl, usubstituert eller med alkyl, CF3, aryl, O-fenyl, klor, S-metyl, S-etyl substituert tienyl, pyridinyl, pyrazolyl, benzodihydropyranyl, isooksazolyl, spesielt l,5-dimetylfuran-3-yl, 2-metyl-5-tert-butyl-furan-3-yl, 3-klortien-2-yl l-(4-klorfenyl)-5-trifluormetyl-pyrazol-4-yl, l-metyl-3-yl
tert-butyl-pyrazol-5-yl, pyridin-4-yl, 2-metyltiopyridin-3-yl, 2-etyltiopyirdin-3-yl, 2-fenoksypyridin-3-yl, 2-klorpyridin-3-yl, 5-metyl-3-(2,6-diklorfenyl)-isoksazol-4-yl, 5-metyl-3-(2-klor-6-fluorfenyl)-isoksazol-4-yl.
9.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge foregående krav,karakterisert vedat forbindelsene foreligger i form av deres fysiologisk godtakbare salter.
10.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 9,karakterisert vedat forbindelsene foreligger som hydroklorid.
11.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 1-8,karakterisert vedat forebindelsene foreligger som hydrat.
12.
Substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat ifølge krav 1,karakterisert vedat det valgt fra gruppen som består av: • 3-(l H-indol-3-yl)-2- {[8-(4-trifluormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyremetylester • {4-[(8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-benzyl}-fosfonsyredietylester • (4-cykloheptyl-piperazin-1 -yl)-[8-(tiofen-2-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-fenyl-piperazin-1 -yl)-metanon • 8-(2-klor-4-nitro-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre cyklopentylamid, • (4-naftalin-2-ylmetyl-piperazin-1 -yl)-(8-fenylmetansulfonyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenetylamid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(l-fenyl-etyl)-amid • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-(3,4-diklorfenyl)-etyl]-amid • 4-dietylamino-benzosyre N'-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-hydrazid • 8-(3-klor-4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-pyrrolidin-1 -yl-etyl)-amid • 8-fenylmetansulfonyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenetyl-amid • 8-benzensulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • [4-(3-fenyl-propyl)-piperazin-l-yl]-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[3-(2-metyl-piperidin-l-yl)-propyl]-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(lH-indol-3-yl)-etyl]-metyl-amid • 8-(5-fiuor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-acetylamino-etyl)-amid • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2-metyl-5-nitro-benzensylfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • 8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,3-dihydro-benzo[1.4]dioksin-2-ylmetyl)-amid • 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(4-fenoksyfenyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(1 -p-tolyl-etyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-benzylamid • 2-fenyl-l-{4-[8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperazin-1 -yl} -etanon • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-
[ 1 -(4-trifluormetyl-benzyl)-pyrrolidin-3-yl]-amid • [8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-o-tolyl-piperazin-1 -yl)-metanon • 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzyl-(2-cyanoetyl)-amid • [8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-(4-tieno[2,3-d]pyrimidin-4-yl-piperazin-1 -yl)-metanon • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(benzo[1.3]diksol-5-ylmetyl)-amid • (3-metyl-4-m-tolyl-piperazin-l-yl)-[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [4-( 1 -fenyl-etyl)-piperazin-1 -yl]-[8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • [4-(2,4-dimetyl-fenyl)-piperazin-l-yl]-[8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2-klor-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopentylamid • (4-naftalen-2-ylmetyl-piperazin-1 -yl)-[8-(3-trifluormetyl-benzensulfonyl)-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-[3-fenyl-2-(toluen-4-sulfonylamino)-propionyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-3-ylmetyl)-amid • 8-(5-fluor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-dimetylamino-etyl)-amid • 8-(4-nitro-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-5-trifluormetyl-benzylamid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzhydryl-amid • 8-[3-fenyl-2-(toluen-4-sulfonylamino)-propionyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-amid • [(8-fenylmetansulfonyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-
amino]-edikksyreetylester
8-(3-dimetylamino-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyre(2-cyano-etyl)-amid
8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyre- [ 1 -(naftalin-2-ylkarbamoyl)-ety l]-amid 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(1 -p-tolyl-etyl)-amid
[4-(4-klor-fenyl)-piperazin-l-yl]-(8-fenylmetansulfonyl-l-oksa-2,8-diaza-
spiro[4.5]dec-2-en-3-yl)-metanon
8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-
(2-benzyloksy-cyklopentyl)-amid
8-acetyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksy lsy re-2,5 -difluor-benzy lamid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(l-naftalin-2-ylmetyl-pyrrolidin-3-yl)-amid • 8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-2-etoksy-benzylamid • 8-(4-etyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 2- {[8-(2,5-diklor-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -ravsyre-1 -allylester-4-tert-butylester • 8-(4-trifluormetoksy benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-naftalin-2-ylamid • 4-{[8-(2-fenyl-cyklopropankarbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-piperidin-l-karboksylsyreetylester • 4-{[8-(2,4-difluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • 8-(toluen-4-sulfonyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-dimetylamino-etyl)-amid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre[2-(4-klor-fenyl)-etyl]-amid • 8-(4-metoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(5-metyl-furan-2-ylmetyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-etyl]-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-amid • 4-[{[8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino]-piperidin-1 -karboksylsyreetylester • 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3,5-diklor-benzy lamid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[l-(3-metoksy-benzyl)-pyrrolidin-3-yl]-amid • 3-(4-naftalin-2-ylmetyl-piperazin-1 -karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyre dimetylamid • 3-{[8-(7.7-dimetyl-2-okso-bicyklo[2.2.1]hept-l-ylmetansulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-benzyloksy-cyklopentyl)-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre 3,4-dimetoksy-benzylamid • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-[4-(3-fenyl-propyl)-piperazin-1 -yl]-metanon • 3-(4-tieno[2,3-d]pyrimidin-4-yl-piperazin-1 -karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimety lamid • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(3,5 -dimetoksy- feny l)-piperazin-1 -yl] -metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-fluor-4-trifluormetyl-benzylamid • 8-(toluen-4-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 4-[(8-butyryl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-piperidin-1 -karboksylsyreetylester • 8-(toluen-4-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-kaboksylsyre-(2-fenyl-cyklopropyl)-amid • [8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(5-metyl-pyrazin-2-karbonyl)-piperazin-1 -yl]-metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-2,4-difluor-benzylamid • 8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(3-fluor-fenyl)-etyl]-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyre-(2,2-difenyl-etyl)-amid
3-[4-(3-fenyl-propyl)-piperazin-l-karbonyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2- en-8-sulfonsyredimetylamid
3-{[8-(3,5-difluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karbony 1] -amino} -propionsyreety lester
8-(propan-l-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyreisobutyl-amid
[4-(3-fenyl-propyl)-piperazin-1 -yl]-[8-(3-trifluormetyl-benzensulfonyl)-1 -
oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon
8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-
[ 1 -(2,3-dihydro-benzo[l .4]dioksin-5-yl)-etyl]-amid
8-butyryl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid 8-(4-trifluormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyrecyklooktylamid • 8-[2-(2-metoksy-etoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-brom-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[3-(metyl-fenyl-amino)-propyl]-amid • 4- {[8-(2-metyl-5-nitro-benzensulfonyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3- karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(4-fluor-fenyl)-piperazin-1 -yl]-metanon • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-metyl-pyridin-3-ylmetyl-amid • 2-(3,4-dilfuor-fenyl)-l-{4-[8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karbonyl]-piperazin-1 -yl} -etanon • 8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 3-{[8-(2-metyl-5-nitro-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-[2-(3-klor-fenoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzyl-fenetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-pyridin-3-ylmetyl-amid • 8-(2,5-diklor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-tetrahydro-furan-2-ylrnetyl)-arnid • 8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-metyl-pyridin-3-ylmetyl-amid • 8-(pyridin-4-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzy lamid • 8-(4-trifluormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreetyl-(2-metyl-allyl)-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(2-fluor-fenyl)-etyl]-amid • 8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(3-fenyl-akryloyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-3-ylmetyl)-amid • 8-(4-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-trilfuormetylsulfanyl-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(5-metyl-furan-2-ylmetyl)-amid • 8-(3-difluor-4-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(7,7-dimetyl-2-okso-bicyklo[2.2.1 ]hept-l -ylmetansulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • 8-(2,4-difluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tetrahydro-furan-2-ylmetyl)-amid • {[8-(3-klor-tiofen-2-karbonyl)- l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karbony 1] -amino} -edikksy reety lester • 4-okso-4- {3-[(tiofen-2-ylmetyl)-karbamoyl]-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-yl} -smørsyremetylester • 8-(2-etylsulfanyl-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 3- {[8-(2-klor-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbony 1] -amino} -propionsyreety lester • 8-(4-trifluormetoksy-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fenoksy-butyryl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • [8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-y 1]- [4-(4-trifluormety l-pyridin-2-yl)-piperazin-1 -yl]-metanon • 8-(2-klor-5-trifluormetyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-benzyloksy-cyklopentyl)-amid • 4-{[8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -piperidin-1 -karboksylsyreetylester • 8-(2-fenoksy-propionyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [2 -(3 -metoksy-feny l)-etyl] -amid • 8-(2-metylsulfanyl-pyridin-3-karbonyl)-2-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopentylamid • 8-(4-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(naftalin-1 -ylmetyl)-amid • 8-(4-trifluormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-fluor-fenyl)-etyl]-amid • 8-(4-brom-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-4-ylmetyl)-amid • 8-(4-metoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(3-trilfuormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3-klor-benzylamid • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-(4-o-tolyl-piperazin-1 -yl)-metanon • (8-fenylmetansulfonyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-(4-pyridin-2-yl-piperazin-1 -yl)-metanon • 8-(4-trifluormetylsulfanyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-fiuor-benzoyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • 2-(3-isobutylkarbamoyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonyl)-benzosyremetylester • 2-[(8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl)-amino]-3-fenyl-propionsyre-tert-butylester • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [ 1 -(2,3 -dihy dro-benzo [ 1,4]dioksin-5 -yl)-ety 1] -amid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(3-imidazol-1 -yl-propyl)-amid • 4-[8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperazin-1 -karboksylsyrebenzy lester • 3-(4-cykloheptyl-piperazin-1 -karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimetylamid • 4-metyl-2-{[8-(tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbony 1] -amino} -pentansyre-tert-buty lester • 8-(3-klor-2-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 2-{[8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbony l)-amino} -4-metyl-pentansy re-tert-buty lester • 3- {[8-(6-klor-2-fluor-3-metyl-benzoyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino}-propionsyreetylester • 8-(2-fenoksy-propionyl)- l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(5-fluor-2-metyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • [8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-[4-(2-metoksy-fenyl)-piperidin-1 -yl]-metanon • 8-(2-klor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2-fenoksy-pyridin-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopentylamid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • l-[8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyreetylester • 8-(2-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2,3-diklor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-heksanoyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopropylmetyl-amid • 8-(2,3-difluor-4-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopropylmetyl-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,5-dimetoksy-benzyl)-furan-2-ylrnetyl-amid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • 8-(4-trilfuormetoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-3 -metoksy-benzy lamid • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-l-metyl-etyl]-amid • 8-(4-trifluormetoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re- [2 -(3,4-diklor-fenyl)- etyl]-amid • 8-[2-(3-klor-fenoksy)-acetyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-(2-pyridin-2-yl-etyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(4-klor-fenyl)-l-metyl-etyl]-amid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(2,6-difluor-3-metyl-benzoyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(2-benzyloksy-acetyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(2,3-diklor-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid • 8-(5-brom-2-metoksy-benzensulfonryl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrecyklopenty lamid • edikksyre-2-(3-benzylkarbamoyl-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-8-yl)-1,1 -dimetyl-2-okso-etylester • 8-[3-(2-klor-6-fiuor-fenyl)-5-metyl-isoksazol-4-karbonyl]-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • [4-(3-fenyl-propyl)-piperazin-1 -yl]- [8-(4-trifluormetoksy-benzensulfony 1)-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-[3-(2-klor-6-fiuor-fenyl)-5-metyl-isoksazol-4-karbonyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzy lamid • 8-(naftalinkarbonyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyreisobutyl-amid • l-[8-(5-tert-butyl-2-metyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyreetylester • 8-(3-difluormetylsulfanyl-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrebenzylamid • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyrefenylamid • 8-(4-metoksy-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(2-fenyl-cyklopropyl)-amid • 8-(4-fenoksy-butyryl)-l-oksa-2,8-diaza[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(3-klor-4-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre(tiofen-2-ylmetyl)-amid • 8-(5-tert-butyl-2-metyl-2H-pyrazon-3-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-etylsulfanyl-etyl)-amid • [8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4,5]dec-2-en-3-yl]-[4-(3-fenyl-propy l)-piperazin-1 -yl] -metanon • 8-(4-trifluormetoksy-benzoyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(pyridin-4-ylmetyl)-amid • benzosyre 2-(3-cyklopentylkarbamoyl-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-karbonyl)-benzylester • 3 - [4-(4-tert-buty 1-benzy l)-piperazin-1 -karbonyl] -1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-8-sulfonsyredimetylamid • {[8-(2-etoksy-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -edikksyreety lester • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(naftalin-l -karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(3-fenyl-propyl)-amid • 8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2,3-dihydro-benzo[1.4]dioksin-2-ylmetyl)-amid • l-[8-(4-tert-butyl-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-piperidin-2-karboksylsyre-etylester • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(3-trifluormetyl-fenyl)-etyl]-amid • 8-[3-(2,6-diklor-fenyl)-5-metyl-isoksazol-4-karbonyl]-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre- [ 1 -(naftalin-2-ylkarbamoyl)-ety l]-amid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 3-(4-klor-fenyl)-2- {[8-(4-metoksy-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino} -propionsyre metylester • 8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-benzyloksy-cyklopentyl)-amid • 8-(3-trilfuormetyl-benzensulfonyl)-1-oksa-2,8.diaza-spiro[4.5]dec-2-en-3-karboksy lsy re-(2 -fenoksy-ety 1) -amid • 8-(2-fenoksy-pyridin-3-karbonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(naftalin-2-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-cyklopropylmetyl-amid • 8-(3-klor-4-fluor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • 8-(2-fenyl-butylryl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(2-cyano-etyl)-amid • 8-(4-fiuor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksy lsy re-2 -fluor-benzy lamid • 8-(3-klor-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-(tiofen-2-ylmetyl)-amid • (4-benzyl-piperazin-l-yl)-[8-(2,5-diklor-benzosulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(3-klor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • (4-benzyl-piperidin-1 -yl)-[8-(3-trifluormetyl-benzosulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(4-brom-benzoyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzy lamid • 8-(4-fluor-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[l-(4-nitro-fenyl)-etyl]-amid • 4-metyl-2- {[8-(3-trifluormetyl-benzensulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karbonyl]-amino]-pentansyre tert-butylester • [4-(4-fluor-feny l)-3,6-dihydro-2H-pyridin-1 -yl]-(8-fenylmetansulfonyl-1 - oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)-metanon • 8-dimetylsulfamoyl-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-[2-(etyl-m-toly l-amino)-etyl] -amid • 8-(2,5-dimetyl-furan-3-karbonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre-benzylamid • (4-cykloheptyl-piperazin-1 -yl)-[8-(4-fluor-benzensulfonyl)-1 -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-yl]-metanon • 8-(2-benzyloksy-acetyl)-l -oksa-2,8-diaza-spiro[4.5]dec-2-en-3-karboksylsyre benzylamid • R,R-8-(5-klor-tiofen-2-sulfonyl)-l-oksa-2,8-diaza-spiro[4.5]dec-2-en-3-
karboksylsyre (2-benzyloksy-cyklopentyl)-amid;
samt deres hydroklorider.
13.
Fremgangsmåter for fremstilling av et substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I)
hvori R , R og R er definert som i et hvilket som helst av kravene 1 til 8,karakterisert vedat (a) forbindelsen med formel (II)
med et metyleneringsmiddel, fortrinnsvis PhaPCHaBr i nærvær av kalium-tert-butylat i THF, til forbindelse (III) (b) forbindelse (III) underkastes en omsetning med etylkloroksimidoacetat (IV)
i nærvær av en base, fortrinnsvis natriumhydrogenkarbonat eller litiumhydroksid, fortrinnsvis i et organisk oppløsningsmiddel, spesielt metanol, diklormetan eller THF, under dannelse av 1-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivater med formel (V) (c) forbindelse (V) omsettes enten direkte eller etter forutgående forsåpning av karboksylsyreetylesterfunksjonen av forbindelse (V), og eventuelt under aktivering av den derved dannede karboksylsyrefunksjonen med et amin med formel HNP<J>R<2>, hvor R<1>og R2 er definert som i et av kravene 1 til 8, til l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivatet med formel (VI) (d) ved fjernelse av BOC-beskyttelsesgruppen fra forbindelse (VI) oppnås forbindelse (I)medR<3>= H
og (e) eventuelt omdannes forbindelse (I) med R3 = H med et syreklorid med formel R<I2>S02C1 til en forbindelse (I) med R<3>= S02R<12>, hvor R<12>er definert som i et hvilket som helst av kravene 1 til 8, eller med et karboksylsyreklorid med formel R<I3>COCl til en forbindelse (I) med R<3>= COR<13>, hvor R<13>er definert som i et hvilket som helst av kravene 1 til 8.
14.
Legemiddel,karakterisert vedat det inneholder minst ett substituert 1-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av hydroklorider, eller i form av solvater, spesielt hydratene.
15.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereiosomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling av smerte, spesielt nevropatisk smerte og/eller kronisk smerte, og/eller for behandling og/eller forebyggelse av migrene.
16.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereoisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling og/eller profylakse av urininkontinens og/eller kløe og/eller tinnitus aurium og/eller diaré.
17.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for anestesi, spesielt lokal anestesi, og/eller for behandling og/eller profylakse av arytmier og/eller emesis og/eller kardiovaskulære lidelser og/eller cerebrale iskemier og/eller alkoholavhengighet og/eller drogeavhengighet og/eller medikamentavhengighet og/eller betennelser og/eller vertigo og/eller som nootropikum (nevrotropikum) og/eller som muskelrelakserende middel.
18.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling og/eller profylakse av inflammatoriske og/eller allergiske reaksjoner og/eller gastritt og/eller ulcere og/eller depresjoner og/eller sjokktilstander og/eller narkolepsi og/eller epilepsi og/eller fedme og/eller astma og/eller glaukom og/eller hyperkinetisk syndrom.
19.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling og/eller profylakse av energiløshet og/eller bulimi og/eller anoreksi og/eller katalepsi og/eller for anksiolyse og/eller for vigilans og/eller libidoøkning.
20.
Anvendelse av minst ett substituert l-oksa-2,8-diaza-spiro[4.5]dec-2-en-derivat med generell formel (I) ifølge krav 1 i form av dets racemater, dets rene stereoisomerer, spesielt enantiomerer eller diastereomerer, eller i form av blandinger av stereisomerene, spesielt enantiomerene eller diastereomerene, i et hvilket som helst blandingsforhold; i fremstilt form eller i form av dets syrer eller dets baser, eller i form av dets salter, spesielt de fysiologisk godtagbare saltene, helt spesielt foretrukket i form av dets hydroklorider, eller i form av dets solvater, spesielt hydratene; for fremstilling av et legemiddel for behandling og/eller profylakse av bipolare lidelser og/eller postmenopausale hetebølger og/eller amyotrofisk lateralsklerose (ALS) og/eller reflekssympatetisk dystrofi (RSD) og/eller spastisk lammelse og/eller "restless leg syndrom" og/eller ervervet nystagmus og/eller multippel sklerose og/eller Morbus Parkinson og/eller Morbus Alzheimer og/eller Morbus Huntington.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10130020A DE10130020A1 (de) | 2001-06-25 | 2001-06-25 | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
PCT/EP2002/006880 WO2003000699A1 (de) | 2001-06-25 | 2002-06-21 | Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20035730D0 NO20035730D0 (no) | 2003-12-19 |
NO20035730L NO20035730L (no) | 2004-02-19 |
NO332217B1 true NO332217B1 (no) | 2012-07-30 |
Family
ID=7689008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035730A NO332217B1 (no) | 2001-06-25 | 2003-12-19 | Substituerte 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater, fremgangsmate for fremstilling derav, anvendelse derav samt legemiddel inneholdende minst ett slikt derivat. |
Country Status (30)
Country | Link |
---|---|
US (2) | US8048890B2 (no) |
EP (1) | EP1401841B1 (no) |
JP (1) | JP4410554B2 (no) |
KR (1) | KR100917112B1 (no) |
CN (1) | CN1315840C (no) |
AR (1) | AR036098A1 (no) |
AT (1) | ATE302782T1 (no) |
AU (1) | AU2002310768B2 (no) |
BR (1) | BR0211053A (no) |
CA (1) | CA2451859C (no) |
CO (1) | CO5540301A2 (no) |
CZ (1) | CZ20033432A3 (no) |
DE (2) | DE10130020A1 (no) |
DK (1) | DK1401841T3 (no) |
EC (1) | ECSP034924A (no) |
ES (1) | ES2245402T3 (no) |
HK (1) | HK1064669A1 (no) |
HU (1) | HU228774B1 (no) |
IL (2) | IL159544A0 (no) |
MX (1) | MXPA03012013A (no) |
NO (1) | NO332217B1 (no) |
NZ (1) | NZ530689A (no) |
PE (1) | PE20030146A1 (no) |
PL (1) | PL214290B1 (no) |
PT (1) | PT1401841E (no) |
RU (1) | RU2296128C2 (no) |
SI (1) | SI1401841T1 (no) |
SK (1) | SK287390B6 (no) |
WO (1) | WO2003000699A1 (no) |
ZA (1) | ZA200400489B (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
BR0313411A (pt) * | 2002-08-14 | 2005-06-28 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para o tratamento de ondas de calor |
DE102004023635A1 (de) * | 2004-05-10 | 2006-04-13 | Grünenthal GmbH | Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate |
DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044813A1 (de) * | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005023784A1 (de) * | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
US8614324B2 (en) * | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
US9340558B2 (en) | 2007-11-02 | 2016-05-17 | Pain Therapeutics Inc. | Filamin a binding anti-inflammatory and analgesic |
EP2498600B1 (en) * | 2008-10-31 | 2016-03-02 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
US8580808B2 (en) * | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
US20100279996A1 (en) * | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
KR101675174B1 (ko) * | 2009-01-26 | 2016-11-10 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 이환형 헤테로사이클릭 스피로 화합물 |
US8580809B2 (en) * | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
DK2882428T3 (en) | 2012-07-13 | 2019-04-15 | Pain Therapeutics Inc | PROCEDURE TO INHIBIT TAU PHOSPHORIZATION |
JP6566867B2 (ja) | 2012-07-13 | 2019-08-28 | ペイン セラピューティクス インコーポレイテッド | 生きている患者でのアルツハイマー病アッセイ |
US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
PT3402784T (pt) | 2016-01-13 | 2020-06-18 | Gruenenthal Gmbh | Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4,5]-decano |
PE20221732A1 (es) | 2016-01-13 | 2022-11-07 | Gruenenthal Chemie | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
RS60855B1 (sr) | 2016-01-13 | 2020-10-30 | Gruenenthal Gmbh | Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
AR107358A1 (es) | 2016-01-13 | 2018-04-25 | Gruenenthal Gmbh | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
BR112018014302B1 (pt) | 2016-01-13 | 2023-10-17 | Grünenthal GmbH | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
CN109793713B (zh) * | 2019-03-26 | 2021-05-28 | 李世系 | 一种用于麻醉的短效催眠镇静的药物组合物及其注射剂制备方法及应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127065C (no) * | 1964-04-22 | |||
GB1227365A (no) * | 1968-07-29 | 1971-04-07 | ||
JPH02164882A (ja) * | 1988-12-20 | 1990-06-25 | Yamanouchi Pharmaceut Co Ltd | スピロ化合物及びその中間体 |
US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5739336A (en) * | 1995-06-23 | 1998-04-14 | Syntex (U.S.A.) Inc. | 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives |
DE19528472A1 (de) * | 1995-08-03 | 1997-02-06 | Boehringer Ingelheim Kg | Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan |
NZ320963A (en) * | 1995-09-29 | 1999-08-30 | Lilly Co Eli | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
ZA972195B (en) * | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
CA2249733A1 (en) * | 1996-03-15 | 1997-09-18 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
AU6780398A (en) * | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
JP4818511B2 (ja) * | 1998-11-18 | 2011-11-16 | ビーエーエスエフ ソシエタス・ヨーロピア | 2−アルキル−3−(4,5−ジヒドロイソオキサゾール−3−イル)ハロベンゼン類の製造方法 |
KR20030000243A (ko) | 2001-06-22 | 2003-01-06 | 이 석 민 | 동물사료 제조방법 및 그에 적합한 기밀 플라스틱백발효용기 |
DE10130020A1 (de) * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
-
2001
- 2001-06-25 DE DE10130020A patent/DE10130020A1/de not_active Withdrawn
-
2002
- 2002-06-19 AR ARP020102303A patent/AR036098A1/es unknown
- 2002-06-21 HU HU0400810A patent/HU228774B1/hu not_active IP Right Cessation
- 2002-06-21 IL IL15954402A patent/IL159544A0/xx unknown
- 2002-06-21 NZ NZ530689A patent/NZ530689A/en not_active IP Right Cessation
- 2002-06-21 PL PL367748A patent/PL214290B1/pl not_active IP Right Cessation
- 2002-06-21 ES ES02735422T patent/ES2245402T3/es not_active Expired - Lifetime
- 2002-06-21 DE DE50204037T patent/DE50204037D1/de not_active Expired - Lifetime
- 2002-06-21 BR BR0211053-9A patent/BR0211053A/pt not_active IP Right Cessation
- 2002-06-21 WO PCT/EP2002/006880 patent/WO2003000699A1/de active IP Right Grant
- 2002-06-21 PE PE2002000537A patent/PE20030146A1/es not_active Application Discontinuation
- 2002-06-21 MX MXPA03012013A patent/MXPA03012013A/es active IP Right Grant
- 2002-06-21 JP JP2003507102A patent/JP4410554B2/ja not_active Expired - Fee Related
- 2002-06-21 KR KR1020037016835A patent/KR100917112B1/ko not_active IP Right Cessation
- 2002-06-21 AT AT02735422T patent/ATE302782T1/de active
- 2002-06-21 RU RU2004100823/04A patent/RU2296128C2/ru not_active IP Right Cessation
- 2002-06-21 SK SK1570-2003A patent/SK287390B6/sk not_active IP Right Cessation
- 2002-06-21 EP EP02735422A patent/EP1401841B1/de not_active Expired - Lifetime
- 2002-06-21 CZ CZ20033432A patent/CZ20033432A3/cs unknown
- 2002-06-21 PT PT02735422T patent/PT1401841E/pt unknown
- 2002-06-21 AU AU2002310768A patent/AU2002310768B2/en not_active Ceased
- 2002-06-21 SI SI200230221T patent/SI1401841T1/sl unknown
- 2002-06-21 CA CA2451859A patent/CA2451859C/en not_active Expired - Fee Related
- 2002-06-21 CN CNB028166825A patent/CN1315840C/zh not_active Expired - Fee Related
- 2002-06-21 DK DK02735422T patent/DK1401841T3/da active
-
2003
- 2003-12-19 NO NO20035730A patent/NO332217B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111723A patent/CO5540301A2/es active IP Right Grant
- 2003-12-22 EC EC2003004924A patent/ECSP034924A/es unknown
- 2003-12-24 IL IL159544A patent/IL159544A/en not_active IP Right Cessation
- 2003-12-24 US US10/744,082 patent/US8048890B2/en not_active Expired - Fee Related
-
2004
- 2004-01-22 ZA ZA200400489A patent/ZA200400489B/en unknown
- 2004-09-30 HK HK04107516A patent/HK1064669A1/xx unknown
-
2011
- 2011-05-26 US US13/116,578 patent/US8557796B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO332217B1 (no) | Substituerte 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater, fremgangsmate for fremstilling derav, anvendelse derav samt legemiddel inneholdende minst ett slikt derivat. | |
US8153795B2 (en) | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | |
EP1601674B1 (en) | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | |
DK2670752T3 (en) | PYRROLOPYRAZINE SPIROCYCLIC PIPERIDINAMIDE AS ION CHANNEL MODULATORS | |
JP2004536095A5 (no) | ||
KR101228378B1 (ko) | 류코트리엔 α4 하이드롤레이즈의 조정제로서의 티아졸로피리딘-2-일옥시-페닐 및 티아졸로피라진-2-일옥시-페닐 아민 | |
AU2002366801B8 (en) | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | |
NO319532B1 (no) | <Beta>karbolinforbindelser,anvendelser av dem og farmasoytiske forbindelser som inneholder dem. | |
EP2227471A1 (en) | Gamma secretase modulators | |
JP2012506396A (ja) | 痛みを治療するためのブラジキニンb1レセプター(b1r)インヒビターとしてのピリミジン−及びトリアジン−スルホンアミド誘導体 | |
US20030229067A1 (en) | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | |
TW202227456A (zh) | Apol1抑制劑及其使用方法 | |
TWI718197B (zh) | 4H-吡唑並[1,5-α]苯並咪唑類化合物晶型及其製備方法和中間體 | |
RU2475485C2 (ru) | Производное пиперидина | |
WO2009124746A1 (en) | Substituted sulfonamide derivatives | |
ES2537591T3 (es) | Nuevos compuestos hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona | |
DK169581B1 (da) | 5,6,7,8-tetrahydro-beta-carbolinderivater og fremgangsmåde til deres fremstilling | |
US20030236295A1 (en) | Tricylic indole compounds having affinity for serotonin receptor | |
BR112012014878A2 (pt) | indolil-piperidinil benzilaminas como inibidores de beta-triptase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |